INFERENCE PROCEDURES IN SEQUENTIAL TRIAL EMULATION WITH SURVIVAL OUTCOMES: COMPARING CONFIDENCE INTERVALS BASED ON THE SANDWICH VARIANCE ESTIMATOR, BOOTSTRAP AND

A PREPRINT

JACKKNIFE

Juliette M. Limozin MRC Biostatistics Unit University of Cambridge juliette.limozin@mrc-bsu.cam.ac.uk Shaun R. Seaman MRC Biostatistics Unit University of Cambridge shaun.seaman@mrc-bsu.cam.ac.uk

Li Su

MRC Biostatistics Unit University of Cambridge li.su@mrc-bsu.cam.ac.uk

ABSTRACT

Sequential trial emulation (STE) is an approach to estimating causal treatment effects by emulating a sequence of target trials from observational data. In STE, inverse probability weighting is commonly utilised to address time-varying confounding and/or dependent censoring. Then structural models for potential outcomes are applied to the weighted data to estimate treatment effects. For inference, the simple sandwich variance estimator is popular but conservative, while nonparametric bootstrap is computationally expensive, and a more efficient alternative, linearised estimating function (LEF) bootstrap, has not been adapted to STE. We evaluated the performance of various methods for constructing confidence intervals (CIs) of marginal risk differences in STE with survival outcomes by comparing the coverage of CIs based on nonparametric/LEF bootstrap, jackknife, and the sandwich variance estimator through simulations. LEF bootstrap CIs demonstrated the best coverage with small/moderate sample sizes, low event rates and low treatment prevalence, which were the motivating scenarios for STE. They were less affected by treatment group imbalance and faster to compute than nonparametric bootstrap CIs. With large sample sizes and medium/high event rates, the sandwich-variance-estimator-based CIs had the best coverage and were the fastest to compute. These findings offer guidance in constructing CIs in causal survival analysis using STE.

Keywords Causal Inference, Confidence Intervals, Inverse Probability Weighting, Marginal Structural Models, Target Trial Emulation, Survival Analysis

1 Introduction

1.1 Target trial emulation with survival outcomes

Target Trial Emulation (TTE) has become a popular approach for causal inference using observational longitudinal data [1, 2]. The goal of TTE is to estimate and make inferences about causal treatment effects that are comparable to those that would be obtained from a target Randomised Controlled Trial (RCT) [1, 3]. TTE can be helpful when it is not possible to conduct this RCT because of time, budget and ethical constraints. Hernán and Robins (2016) have proposed a formal framework for TTE [1], which highlights the need to specify the target trial's protocol, i.e., the protocol of the RCT that would have ideally been conducted, in order to guide the design and analysis of the emulated trial using data extracted from observational databases such as disease registries or electronic health records. The protocol should include the eligibility criteria, treatment strategies, assignment procedures, outcome(s) of interest, follow-up periods, causal contrast of interest and an analysis plan; see some step-by-step guides to TTE in [4], [5], [6].

In TTE there are various sources of bias that must be addressed. Firstly, unlike in an RCT, non-random assignment of treatment at baseline must be accounted for when estimating the causal effect (intention-to-treat or per-protocol) of a treatment in an emulated trial. Secondly, similar to an RCT, it is necessary to account for censoring caused by loss to follow-up in an emulated trial. Thirdly, when the per-protocol effect is the causal effect of interest, it is also necessary to handle non-adherence to assigned treatments. To address these issues in TTE with survival outcomes, a useful approach is to fit a marginal structural Cox model (MSCM) using inverse probability weighting (IPW) [7, 8, 9, 10, 11, 12, 13], after first artificially censoring the patients' follow-up at the time of treatment non-adherence [14, 15, 16]. Baseline confounders are included in this MSCM as covariates to adjust for the non-random treatment assignment at baseline using regression. The inverse probability weights are the product of two sets of time-varying weights: one to address selection bias from censoring due to loss to follow-up, and one to address selection bias from the artificial censoring due to treatment non-adherence. Counterfactual hazard ratios can be estimated from the fitted MSCM using weighted data. A modification of this approach is to discretise the survival time and replace the MSCM with a pooled logistic regression model [9, 10]. Provided that the probability of failure between the discrete times is small, this pooled logistic model well approximates the MSCM [17].

The counterfactual hazard ratio has been criticised as lacking a causal interpretation, and it has been proposed that other estimands be used instead, e.g., the marginal risk difference (MRD) [18, 19, 20]. The MRD over time can be estimated by first using the counterfactual hazard ratio estimates from a marginal structural model (MSM) together with an estimate of the baseline hazard to predict the survival probabilities of the patients in the emulated trial under two scenarios: when all are treated and when none are treated. For each scenario, the predicted survival probabilities are averaged over all enrolled patients. The estimate of the MRD is then calculated as the difference between these two averages [16, 20].

1.2 Constructing confidence intervals in sequential trial emulation

A potential problem when emulating a trial is that the number of treated and/or untreated patients eligible for inclusion in a trial that begins at any *given* time may be small. This can be addressed by sequential trial emulation (STE) [14, 21], which takes advantage of the fact that patients may meet the eligibility criteria for the target trial multiple times during their follow-up in an observational database. In STE, a sequence of target trials is emulated, each starting at a different time. The data from these sequential trials are pooled and analysed to produce an overall estimate of the treatment effect [20]. This approach was first proposed by Hernán et al. (2008) [14] and Gran et al. (2010) [21] as a simple way to improve the efficiency of treatment effect estimation relative to emulating a *single* trial. There have been several applications of STE; see Keogh et al. (2023) [20] for a list.

Despite the increasing popularity of TTE, there is a lack of research on different methods for constructing confidence intervals (CIs) of treatment effects in STE. The sandwich variance estimator, bootstrap or jackknife can be used to obtain a variance estimate of the parameter estimates in an MSM by accounting for correlations induced by the same patient being eligible for multiple trials. In causal survival analysis with IPW to adjust for baseline confounding of point treatments [22, 23], the sandwich variance estimator of Lin and Wei (1989) [24] is frequently used. However, this estimator does not account for the uncertainty due to weight estimation, and can consequently overestimate the true variance [22, 23]. More complex sandwich variance estimators that account for this uncertainty are available. Shu et al. (2021) [23] proposed a variance estimator for the hazard ratio of a point treatment in an MSCM with IPW used for baseline confounding only. Enders et al. (2018) [25] developed a sandwich variance estimator for the hazard ratios in an MSCM when IPW is used to deal with treatment switching and censoring due to loss to follow-up. They found no substantial differences in the performance of the simple sandwich variance estimator and their sandwich variance estimator, and the latter performed comparatively poorly in scenarios with small sample sizes and many confounders. No off-the-shelf software has implemented the variance estimator by Enders et al. (2018) [25].

Bootstrap has been recommended as an alternative to the sandwich variance estimator because it accounts for uncertainty in weight estimation. In the simple setting where IPW is used to estimate the effect of a point treatment on a survival outcome, Austin (2016) found that bootstrap CIs performed better than the sandwich-variance-estimator-based CIs when the sample size was moderate (1000) [22]. In the setting with continuous and binary outcomes, Austin (2022) found that when sample sizes were small (250 or 500) to moderate (1000), bootstrap resulted in more accurate estimates of standard errors than sandwich variance estimators. However, bootstrap CIs did not achieve nominal coverage when the sample sizes were small to moderate and the treatment prevalence was either very low or very high [26]. Mao et al. (2018) observed similar results when constructing CIs of hazard ratios for a binary point treatment using IPW: with small (500) and moderate (1000) sample sizes and strong associations between confounders and treatment assignment, both the sandwich variance estimator and bootstrap resulted in under-coverage of CIs [27]. For the longitudinal setting with binary time-varying treatments, Seaman and Keogh (2023) found that with moderate (1000) sample sizes, bootstrap and the sandwich variance estimator both led to slightly under-coverage of CIs for hazard ratios in an MSCM but with no notable difference between the two methods [28]. With

small (250, 500) sample sizes, the coverage of the CIs deteriorated, but bootstrap CIs had coverage closer to the nominal level than the sandwich-estimator-based CIs [28].

Jackknife resampling has been used in TTE to construct CIs of hazard ratio and risk difference (see [29] and [30] for recent examples). Gran et al. (2010) also used jackknife to construct the CI of the hazard ratio of a binary treatment in the STE setting because in their analysis bootstrap led to non-convergence problems due to the large number of covariates used [21]. Jackknife could be advantageous when the sample size is small because it is computationally faster than bootstrap and it is less likely to lead to non-convergence problems since only one patient's data are left out in each jackknife sample.

The works mentioned above all focused on variance estimation and CIs for counterfactual hazard ratios, which are often chosen as the estimand in the literature of TTE with survival outcomes [14, 31]. While these works were not researched specifically for TTE with survival outcomes, they could be easily applied to such a setting. However, in the more complex setting of STE, less attention appears to be paid to the development and evaluation of CI construction methods. There is a lack of research on comparing the nonparametric bootstrap and the sandwich variance estimator for constructing CIs of the MRD in various settings of STE. It is also desirable to develop computationally more efficient CI methods than nonparametric bootstrap.

1.3 The contribution of this article

To fill this gap, we carry out an extensive simulation study to compare different methods for constructing a CI of the MRD in STE with a survival outcome. The first method uses the sandwich variance estimator that ignores the uncertainty caused by weight estimation. The second method is nonparametric bootstrap. This has the drawback of being computationally expensive. For this reason, the third method that we investigate is the computationally less intensive Linearised Estimating Function (LEF) bootstrap. Hu and Kalbfleisch (2000) [32] first developed the estimating function bootstrap approach. In settings with cross-sectional/longitudinal survey data with design weights, Rao and Tausi [33] and Binder et al. [34] proposed the LEF bootstrap to improve computational efficiency and to avoid ill-conditioned matrices when fitting logistic models to bootstrap samples. We develop two forms of the LEF bootstrap for the STE setting. The fourth method is jackknife resampling. In our simulation study, we consider scenarios with varying sample sizes, treatment prevalence, outcome event rates, and strength of time-varying confounding. Our results provide some guidance to practitioners on which methods could perform better in different settings.

The article is organised as follows. In Section 2 we introduce the HIV Epidemiology Research Study (HERS) data as a motivating example and describe a protocol of STE based on the HERS data. Section 3 describes the notation, causal estimand, causal assumptions and MRD estimation procedure in STE. In Section 4, we describe the CI construction methods that we compare in this article, including our proposed LEF bootstrap CIs. Section 5 presents our simulation study. In Section 6, we apply STE to the HERS data. We conclude in Section 7 with a discussion.

2 HIV Epidemiology Research Study: a motivating example

The HIV Epidemiology Research Study (HERS) included 1310 women with, or at high risk of, HIV infection at four sites (Baltimore, Detroit, New York, Providence) enrolled between 1993-1995 and followed up to 2000 [35]. The HERS had 12 approximately six-monthly scheduled visits, where clinical, behavioural, and sociological outcomes and (self-reported) treatment were recorded.

Following Ko et al. (2003) [35] and Yiu and Su (2022) [36], we aim to estimate the causal effect of (self-reported) Highly Active AntiRetroviral Treatment (HAART) on all-cause mortality among HIV-infected patients in the HERS cohort. Clinical and demographic variables related to treatment assignment and disease progression were available, including CD4 cell count, HIV viral load, self-reported HIV symptoms, race, and the site in which a patient was enrolled. Following Yiu and Su (2022) [36], we treat visit 8 in 1996 as the baseline of the observational cohort, as HAART was more widely used and recorded in the HERS by then. There were 584 women assessed at visit 8. Time of death during follow-up was recorded exactly and there were 24 deaths in total. Some patients were also lost to follow-up, with 179 patients assessed at the last follow-up visit 12. Yiu and Su (2022) conducted their analysis with standard MSMs with IPW by defining the time-varying treatment as ordinal with 3 levels: "no treatment", "antiretroviral therapy other than HAART", and "HAART" [36]. In our analysis we consider a binary treatment: "HAART" versus "no HAART". A hypothetical RCT (the target trial) to estimate the per-protocol effect of HAART (vs. other or no treatment) on all-cause mortality could be emulated using the HERS data. The target trial protocol can be found in Table 16 of the Supplementary Materials.

As mentioned in Section 1, a practical problem for TTE is that if we only emulate a single trial, the number of patients who initiate (i.e. start to receive) the treatment at baseline and the number of outcome events among them could be small. In the HERS, only 76 patients initiated the HAART when baseline is defined as visit 8. By emulating a *sequence* of target trials and combining their analyses, more efficient estimates of treatment effects can be obtained. For example, an additional 62 women initiated HAART at visit 9 of the HERS, and so would be in the treatment arm of an emulated trial with baseline defined as visit 9.

In Section 6 we emulate 5 sequential trials from the HERS data labelled from 0 to 4 with sequential enrollment periods so that the trials start at visits 8, 9, 10, 11 and 12, respectively. The trial protocol, and more specifically the eligibility criteria, remain the same across all 5 trials, which in our example means that patients must have no prior use of HAART before the baseline of the trial. The study horizons differ: trial 0 has 4 follow-up assessments at visits 9 to 12; trial 1 has 3 follow-up assessments at visits 10 to 12; and so on. Trial 4 only has a baseline assessment at visit 12 and no further follow-up. This approach means that we can use data from patients who started receiving the HAART later in the HERS cohort. Table 1 presents tabulation of the HERS data prepared for STE, where we note that the total number of patients in the treatment arm is increased from 76 (in a single trial with baseline at visit 8) to 234 by using the STE approach. A patient can be eligible for multiple trials. For example, a patient who had not been receiving HAART at visits 8 and 9 but started to receive HAART from visit 10 will be eligible as a member of the control arm in trials 0 and 1, and as a member of the treatment arm in trial 2.

Moreover, this patient's follow-up in trials 0 and 1 will be artificially censored at visit 10. Figure 1 of the Supplementary Materials provides a schematic illustration of the STE approach.

[Table 1 about here.]

3 Estimation of the per-protocol effect in sequentially emulated trials

3.1 Setting and notation

Consider an observational study in which n patients are followed up from time t_0 until the earliest of the event of interest, loss to follow-up, and the end of the study. For each patient, time-independent variables are measured at time t_0 , and time-varying variables are measured at regular times $t_0 < t_1 < ... < t_{n_v-1}$ during follow-up, where t_{n_v} denotes the time of the end of the study $(t_{n_v-1} < t_{n_v})$ and n_v is therefore the maximum number of study visits before t_{n_v} . Data on each patient are assumed to be independent and identically distributed. Data from this study will be used to create data for a sequence of n_v trials. The m^{th} sequential trial (i.e., trial $m, m = 0, \ldots, n_v - 1$) begins at time t_m , includes patients who are eligible for enrolment at this time, and ends at time t_{n_v} . Hence, within this trial, the time-varying variables are measured at times t_m, \ldots, t_{n_v-1} . We shall refer to these $n_v - m$ measurement times as the trial visits for trial m. For example, trial visit 0 in trial m takes place at time t_m and trial visit $n_v - m - 1$ takes place at time t_{n_v-1} . For each of the n patients in the observational study, we define the following variables.

- E_m is an indicator of whether the patient is eligible $(E_m = 1)$ or not $(E_m = 0)$ for trial m.
- $Y_{m,k} = 1$ (k = 0, 1, ...) if the patient experiences the event of interest in time interval [t_m, t_{m+k+1}), and $Y_{m,k} = 0$ otherwise.
- V denotes the patient's vector of time-independent covariates measured at time t_0 .
- $A_{m,k}$ and $L_{m,k}$ denote, respectively, the patient's treatment and time-varying covariates measured at time t_{m+k} .
- $C_{m,k}$ is an indicator that the patient is censored due to loss to follow-up in the interval $[t_{m+k}, t_{m+k+1})$. So, if $C_{m,k} = 1$ then $Y_{m,k+1}, Y_{m,k+2}, ..., Y_{m+1,k}, Y_{m+1,k+1}, ...$ are not observed.

 $Y_{m,k}$, $A_{m,k}$, $L_{m,k}$ and $C_{m,k}$ will serve as, respectively, the outcome indicator, the binary treatment indicator, the timevarying covariates and the censoring indicator at trial visit k (k = 0, 1, ...) in trial m ($m = 0, ..., n_v - 1$). Also, we shall use the overbar to denote variable history, for example, $\overline{A}_{m,k} = (A_{m,0}, ..., A_{m,k})$ denotes the patient's history of treatment up to trial visit k in trial m, and define $\overline{0} = (0, ..., 0)$ and $\overline{1} = (1, ..., 1)$. We assume the temporal ordering $(L_{m,k}, A_{m,k}, Y_{m,k}, C_{m,k})$ within $[t_{m+k}, t_{m+k+1})$, $\forall m, k$.

For a patient enrolled in trial m (i.e., with $E_m = 1$) and for \overline{a}_k equal to either $\overline{0}$ or $\overline{1}$, we define the potential variable $Y_{m,k}^{\overline{a}_k}$ to be a binary indicator that the patient would have experienced the event of interest during the time interval $[t_m, t_{m+k+1})$ if he/she/they had, possibly contrary to fact, received treatment $a \in \{0, 1\}$ since the baseline of trial m, i.e., from time t_m up to time t_{m+k} . Analogously, $L_{m,k}^{\overline{a}_k}$ denotes the potential time-varying covariates the patient would have if he/she/they had

received this treatment since t_m up to time t_{m+k} . Note that $Y_{m,k}^{\overline{a}_k}$ and $L_{m,k}^{\overline{a}_k}$ are not defined for patients ineligible for trial m, i.e. patients with $E_m = 0$. We shall omit the explicit conditioning on $E_m = 1$ when describing the causal estimated in the next section.

3.2 Causal estimand and assumptions

We define the per-protocol effect in trial m in terms of the MRD. The MRD at trial visit k in trial m is the difference between the marginal cumulative incidence at time t_{m+k} if all patients in the population eligible for trial m were always treated by time t_{m+k} and the marginal cumulative incidence if they were not treated at all by time t_{m+k} [20]. That is,

$$\mathbf{MRD}_{m}(k) = \Pr(Y_{m,k}^{\overline{a}_{k}=\overline{1}} = 1) - \Pr(Y_{m,k}^{\overline{a}_{k}=\overline{0}} = 1)$$
(1)

Identification of (1) requires standard causal assumptions of no interference, consistency, positivity, no unmeasured confounding of treatment assignment at the trial baseline, and positivity and sequential ignorability of treatment adherence [20]. Positivity and sequential ignorability of censoring must also hold. Details of these assumptions are provided in Section 2 of the Supplementary Materials. Equation (1) can be written equivalently as

$$\begin{aligned} \mathsf{MRD}_{m}(k) &= \Pr(Y_{m,k}^{\overline{a}_{k}=\overline{0}}=0) - \Pr(Y_{m,k}^{\overline{a}_{k}=\overline{1}}=0) \\ &= \mathbb{E}_{V,L_{m,0}} \left\{ \Pr(Y_{m,k}^{\overline{a}_{k}=\overline{0}}=0 \mid V, L_{m,0}) - \Pr(Y_{m,k}^{\overline{a}_{k}=\overline{1}}=0 \mid V, L_{m,0}) \right\} \end{aligned}$$
(2)

The counterfactual survival probabilities in (2) can be written in terms of counterfactual discrete-time hazards as follows:

$$\Pr(Y_{m,k}^{\bar{a}_k=\bar{a}}=0) = \mathbb{E}_{V,L_{m,0}}\left[\left\{1 - \Pr\left(Y_{m,0}^{a_0=a}=1 \mid V, L_{m,0}\right)\right\} \prod_{j=1}^k \left\{1 - \Pr\left(Y_{m,j}^{\bar{a}_j=\bar{a}}=1 \mid Y_{m,j-1}^{\bar{a}_{j-1}=\bar{a}}=0, V, L_{m,0}\right)\right\}\right],$$
$$a \in \{0,1\}$$

3.3 Marginal structural model with inverse probability weighting

We assume the following MSM in the form of a pooled logistic model with regression parameters β :

$$\log i \left\{ \Pr \left(Y_{m,k}^{\overline{a}_k = \overline{a}} = 1 \mid Y_{m,k-1}^{\overline{a}_{k-1} = \overline{a}} = 0, V, L_{m,0} \right) \right\} = \beta_0(m) + \beta_1(k) + \beta_2 \cdot a + \beta_3^{\mathsf{T}} V + \beta_4^{\mathsf{T}} L_{m,0}, \tag{3}$$
$$a \in \{0, 1\},$$

where $\beta_0(m)$ is a trial-specific intercept and $\beta_1(k)$ is the baseline hazard at trial visit k. This MSM could be fitted separately in each emulated trial. However, a combined analysis can be more efficient and may be necessary when the number of treated patients for some trials are small. This involves making modelling assumptions about how the MSM parameters vary across trials. For example, Danaei et al. (2013) allowed a trial-specific intercept term $\beta_0(m)$ but assumed that the coefficient for treatment β_2 was the same in all trials [31], thus allowing for borrowing strength across trials for treatment effect estimation. Parametric forms or splines can be used for $\beta_0(m)$ and $\beta_1(k)$. In (3) it is also assumed that the baseline hazard and the coefficients of V and $L_{m,0}$ do not vary across trials. Interactions between trials, trial follow-up visits, treatment and baseline covariates can be included as well. Keogh et al. (2023) discussed the MSM specification in STE and recommended that formal tests be performed for the inclusion of any covariate interaction [20].

Given the baseline covariates V and $L_{m,0}$, we assume no unmeasured confounding of baseline treatment assignment. Thus if all patients adhere to the treatment assigned and no censoring occurs, the MSM parameters can be estimated by fitting the pooled logistic model in (3) to the observed data in the emulated trials. In practice, not all eligible patients for trial m would adhere to their assigned treatments. We artificially censor patients' follow-up in trial m at the time at which they cease to adhere to the treatment $A_{m,0}$ received at the baseline of trial m [14, 21]. We use IPW as mentioned in Section 1 to account for the artificial censoring and censoring due to loss-to-follow-up.

To address artificial censoring due to treatment switching and censoring due to loss to follow-up, we calculate each patient's stabilised inverse probability of treatment weight $sw_{m,k}^A$ and stabilised inverse probability of censoring weight $sw_{m,k}^C$ at trial visit k in trial m. The formulae of these weights are provided Section 3 of the Supplementary Materials. Each patient's stabilised inverse probability of treatment and censoring weight (SIPTCW) [31, 15, 16, 7] at trial visit k in trial m is therefore $sw_{m,k}^{AC} = sw_{m,k}^A \times sw_{m,k}^C$.

We follow the method of Danaei et al. (2013) [31], who fitted logistic models to the treatment and censoring data from the original observational study to estimate the conditional probabilities used for calculating SIPTCWs. They used observed treatment and censoring data of each patient from the visits that correspond to the baselines of the eligible trials until the trial visits where the patient stopped adhering to the assigned treatments or the last trial visits. If patients were eligible for multiple trials, duplicates of the treatment and censoring data within patients were discarded.

We pool the observed data from the n_v trials and fit the MSM in (3) to the pooled, artificially censored and weighted data to obtain a point estimate $\hat{\beta}$ of the MSM parameters β in (3).

3.4 Estimating the causal estimand

The MRD at trial visit k in trial m can be estimated using the parameter estimates $\hat{\beta}$ from the MSM by the empirical standardization formula:

$$\widehat{\text{MRD}}_{m}(k) = \frac{1}{n_{m}} \sum_{i=1}^{n} E_{m,i} \prod_{j=0}^{k} \left\{ 1 - \log i t^{-1} \left\{ \mu(j,m,a=0,V_{i},L_{m,0,i};\hat{\beta}) \right\} \right\} - \frac{1}{n_{m}} \sum_{i=1}^{n} E_{m,i} \prod_{j=0}^{k} \left\{ 1 - \log i t^{-1} \{ \mu(j,m,a=1,V_{i},L_{m,0,i};\hat{\beta}) \} \right\},$$
(4)

where *i* indexes the patient in the original observational study, $n_m = \sum_{i=1}^n E_{m,i}$ is the total number of patients enrolled in trial *m*, logit⁻¹(·) = exp(·)/{1 + exp(·)} and $\mu(j, m, a, L_{m,0}, V; \hat{\beta}) = \hat{\beta}_0(m) + \hat{\beta}_1(j) + \hat{\beta}_2 \cdot a + \hat{\beta}_4^T V + \hat{\beta}_4^T L_{m,0}$ for j = 0, ..., k. $\widehat{MRD}_m(k)$ is an estimate of the MRD at trial visit k in the population of patients eligible for trial m. Alternatively, we could standardise to a population characterised by a different distribution of $(V, L_{m,0})$.

To summarise, the MRD in (2) is estimated by the following steps:

- 1. Estimate the SIPTCWs using data from the observational study.
- 2. Expand the observational data by assigning patients to eligible sequential trials and artificially censor patients' trial follow-up when they were no longer adhering to the treatment assigned at the baseline of each sequential trial.
- 3. Estimate the MSM for the sequential trials using the expanded, artificially censored data with the estimated weights in Step 1.
- 4. Create two datasets containing patients from a target population with their baseline covariates data, setting their treatment assignment to either treatment arm, and calculate the estimated counterfactual survival probabilities of each patient in each of these two datasets.
- 5. Estimate the MRD by averaging the survival probabilities in each of the two datasets and taking the difference between these two averages, as is done in equation (4).

In this article, we use the R package TrialEmulation [37] (see Section 4 of Supplementary Materials) to implement these steps.

4 Constructing confidence intervals of the marginal risk difference

In this section, we describe the methods for constructing CIs of the MRD based on the simple sandwich variance estimator, nonparametric bootstrap, LEF bootstrap and jackknife resampling.

4.1 Sandwich variance estimator

The simple sandwich variance estimator accounts for the inverse probability weights and the correlation induced by patients being eligible to multiple trials [9, 31]. Specifically, for the pooled logistic regression model in (3), the simple sandwich variance estimator of $\hat{\beta}$ is

$$\hat{\boldsymbol{\Sigma}} = \left\{ \sum_{i=1}^{n} \frac{\partial \mathbf{U}_{i}(\boldsymbol{\beta})}{\partial \boldsymbol{\beta}^{\mathrm{T}}} \right\}_{\boldsymbol{\beta} = \hat{\boldsymbol{\beta}}}^{-1} \left\{ \sum_{i=1}^{n} \mathbf{U}_{i}(\hat{\boldsymbol{\beta}}) \mathbf{U}_{i}(\hat{\boldsymbol{\beta}})^{\mathrm{T}} \right\} \left\{ \frac{\partial \mathbf{U}_{i}(\boldsymbol{\beta})}{\partial \boldsymbol{\beta}^{\mathrm{T}}} \right\}_{\boldsymbol{\beta} = \hat{\boldsymbol{\beta}}}^{-1}$$

where $\mathbf{U}_i(\hat{\boldsymbol{\beta}})$ is the weighted score function of the pooled logistic model evaluated at $\hat{\boldsymbol{\beta}}$ for patient *i*.

We follow the parametric bootstrap algorithm of Mandel (2013) to construct simulation-based CIs of the MRD as follows [38]:

1) Obtain the parameter estimate $\hat{\beta}$ and the sandwich variance estimate $\hat{\Sigma}$ of the MSM in (3).

- 2) Draw an i.i.d. sample $\beta^{(1)}, ..., \beta^{(S)}$ of size S (say S = 500) from the multivariate Normal distribution with mean $\hat{\beta}$ and variance $\hat{\Sigma}$.
- 3) For each vector $\beta^{(s)}$ (s = 1,...,S), estimate the MRD at each trial visit by setting $\beta^{(s)}$ as the MSM parameters.
- Use the 2.5th and 97.5th percentiles of these S MRD estimates at each trial visit as the lower and upper bounds of the 95% CI.

This is currently the only CI method implemented in the TrialEmulation package.

4.2 Nonparametric bootstrap with the pivot method

We use the non-Studentized pivot method [39] to construct CIs based on nonparametric bootstrap. Specifically, we follow the steps described below:

- 1) Draw B bootstrap samples from the observational data, treating the n patients as the resampling units.
- 2) For each bootstrap sample b (b = 1, ..., B), obtain the bootstrap parameter estimate $\hat{\beta}^{(b)}$ and estimate the MRD at trial visit k in trial m, MRD_m(k), using the method in Section 3.
- 3) Define the lower and upper bounds of the 95% CI for the MRD at each trial visit k in trial m as, respectively, $2\widehat{\text{MRD}}_m(k) - \widehat{\text{MRD}}_m(k)^*_{(0.975)}$ and $2\widehat{\text{MRD}}_m(k) - \widehat{\text{MRD}}_m(k)^*_{(0.025)}$, where $\widehat{\text{MRD}}_m(k)$ is the point estimate of the MRD at trial visit k in trial m estimated from the original dataset, and $\widehat{\text{MRD}}_m(k)^*_{(0.025)}$, $\widehat{\text{MRD}}_m(k)^*_{(0.975)}$ are the 2.5th and 97.5th percentiles of the B bootstrap MRD estimates at trial visit k in trial m, respectively.

4.3 Linearised Estimating Function bootstrap

The main advantages of LEF bootstrap over nonparametric bootstrap are reduced computational time and non-convergence issues [34, 32]. In terms of computational time, unlike the nonparametric bootstrap, which involves fitting a regression model to each bootstrap sample, LEF bootstrap requires fitting this model only once to the original dataset. This can reduce computational time considerably, especially when iterative procedures are used to fit the model. In terms of non-convergence issues, Binder et al. (2004) found that when using nonparametric bootstrap for logistic regression it was possible to have several bootstrap samples for which the parameter estimation algorithm would not converge, due to ill-conditioned matrices that were not invertible [34]. For both reasons, LEF bootstrap may have advantages in our STE setting, where logistic regression models are used both for estimating the SIPTCWs and for fitting the MSM. We now explain how LEF bootstrap works in the general situation where the goal is to construct a CI for some function of a parameter vector θ . In Section 4.3.1, we shall describe how to apply this general method to the specific setting of STE.

Let $\mathbf{U}(\theta)$ denote the estimating function for θ (note that \mathbf{U} here is different from \mathbf{U}_i in Section 4.1). Let $\mathbf{U}^{\text{org}}(\theta)$ denote the sum of $\mathbf{U}(\theta)$ over the *n* patients in the original dataset. Then $\mathbf{U}^{\text{org}}(\theta) = \mathbf{0}$ is the estimating equation for θ based on the original dataset. Let $\hat{\theta}$ denote the estimate of θ obtained by solving this equation. Now suppose that *B* bootstrap samples have been generated by resampling with replacement from this original dataset. Let $\mathbf{U}^{(b)}(\theta) = \mathbf{0}$ denote the estimating

equation for θ based on the b^{th} bootstrap sample, and let $\hat{\theta}^{(b)}$ denote the corresponding estimate of θ (b = 1, ..., B). If we apply Taylor linearisation to the function $\mathbf{U}^{(b)}(\theta)$ around $\hat{\theta}$, we obtain

$$\mathbf{U}^{(b)}(\boldsymbol{\theta}) \approx \mathbf{U}^{(b)}(\hat{\boldsymbol{\theta}}) + \left\{ \frac{\partial \mathbf{U}^{(b)}(\boldsymbol{\theta})}{\partial \boldsymbol{\theta}} \right\}_{\boldsymbol{\theta} = \hat{\boldsymbol{\theta}}} (\boldsymbol{\theta} - \hat{\boldsymbol{\theta}}).$$

From this and the fact that $\mathbf{U}^{(b)}(\hat{\boldsymbol{ heta}}^{(b)}) = \mathbf{0}$ by definition, we obtain

$$\mathbf{0} \approx \mathbf{U}^{(b)}(\hat{\boldsymbol{\theta}}) + \left\{ \frac{\partial \mathbf{U}^{(b)}(\boldsymbol{\theta})}{\partial \boldsymbol{\theta}} \right\}_{\boldsymbol{\theta} = \hat{\boldsymbol{\theta}}} (\hat{\boldsymbol{\theta}}^{(b)} - \hat{\boldsymbol{\theta}})$$

Rearranging the terms, we get

$$\hat{\boldsymbol{\theta}}^{(b)} \approx \hat{\boldsymbol{\theta}} - \left\{ \frac{\partial \mathbf{U}^{(b)}(\boldsymbol{\theta})}{\partial \boldsymbol{\theta}} \right\}_{\boldsymbol{\theta} = \hat{\boldsymbol{\theta}}}^{-1} \mathbf{U}^{(b)}(\hat{\boldsymbol{\theta}}).$$

Replacing the matrix $\left\{ \partial \mathbf{U}^{(b)}(\boldsymbol{\theta}) / \partial \boldsymbol{\theta} \right\}_{\boldsymbol{\theta} = \hat{\boldsymbol{\theta}}}^{-1}$ by $\left\{ \partial \mathbf{U}^{\mathrm{org}}(\boldsymbol{\theta}) / \partial \boldsymbol{\theta} \right\}_{\boldsymbol{\theta} = \hat{\boldsymbol{\theta}}}^{-1}$, we obtain the following approximation of $\hat{\boldsymbol{\theta}}^{(b)}$:

$$\hat{\boldsymbol{\theta}}_{\text{LEF}}^{(b)} \approx \hat{\boldsymbol{\theta}} - \left\{ \frac{\partial \mathbf{U}^{\text{org}}(\boldsymbol{\theta})}{\partial \boldsymbol{\theta}} \right\}_{\boldsymbol{\theta} = \hat{\boldsymbol{\theta}}}^{-1} \mathbf{U}^{(b)}(\hat{\boldsymbol{\theta}}) = \hat{\boldsymbol{\theta}} + \text{vcov}(\hat{\boldsymbol{\theta}})\mathbf{U}^{(b)}(\hat{\boldsymbol{\theta}}), \tag{5}$$

where $vcov(\hat{\theta})$ is the model-based variance matrix based on the original dataset.

We propose the following two ways of using LEF bootstrap to construct CIs for the MRD.

4.3.1 Approach 1: LEF bootstrap for the MSM parameters

This approach applies Taylor linearisation only to the estimating function of the pooled logistic regression for the MSM in (3), with the SIPTCWs first being estimated from each bootstrap sample by fitting the corresponding logistic models to that bootstrap sample, as is done in nonparametric bootstrap. We shall use $w_{m,k,i}$ to denote the estimated SIPTCW for patient i (i = 1, ..., n) in the original dataset at trial visit k in trial m (if patient i is not enrolled in trial m, i.e. $E_{m,i} = 0$, then $w_{m,k,i} = 0$). Analogously, $w_{m,k,i}^{(b)}$ will denote the estimated SIPTCW for patient i at trial visit k in trial m in the b^{th} bootstrap sample. The procedure is as follows.

- (1) Estimate $w_{m,k,i}$ using the original dataset. Using $w_{m,k,i}$, fit the weighted pooled logistic model to the original dataset and obtain the point estimate $\hat{\beta}$ of the MSM parameters.
- (2) Create B bootstrap samples using the n patients as resampling units. Using the b^{th} bootstrap sample, estimate $w_{m,k,i}^{(b)}$ for the patients in the b^{th} bootstrap sample (b = 1, ..., B).
- (3) Calculate approximate bootstrap parameter estimate $\hat{\beta}_{\text{LEF}}^{(b)}$ from the b^{th} bootstrap sample using the weights $w_{m,k,i}^{(b)}$ according to the formula in equation (5).

For our case with a pooled logistic regression for MSM in (3), this formula can be written as

$$\hat{\boldsymbol{\beta}}_{\text{LEF}}^{(b)} = \hat{\boldsymbol{\beta}} - \left(\sum_{m=0}^{n_v-1} \sum_{i=1}^n E_{m,i} \sum_{k=0}^{q_{m,i}-1} w_{m,k,i} \log it^{-1} \{\mu_{m,k,i}(\hat{\boldsymbol{\beta}})\} \right) \\ \left[1 - \log it^{-1} \{\mu_{m,k,i}(\hat{\boldsymbol{\beta}})\} \right] \mathbf{X}_{m,k,i} \mathbf{X}_{m,k,i}^{\mathsf{T}} \right)^{-1} \\ \times \sum_{m=0}^{n_v-1} \sum_{i=1}^n E_{m,i}^{(b)} \sum_{k=0}^{q_{m,i}-1} w_{m,k,i}^{(b)} \mathbf{X}_{m,k,i}^{(b)} \left[Y_{m,k,i}^{(b)} - \log it^{-1} \{\mu_{m,k,i}^{(b)}(\hat{\boldsymbol{\beta}})\} \right],$$
(6)

where $E_{m,i}$ and $E_{m,i}^{(b)}$ are the eligibility indicators of patient *i* for trial *m* in the original dataset and in the *b*th bootstrap sample, respectively; $q_{m,i}$ is the total number of trial visits made by patient *i* eligible in trial *m* before being artificially censored, loss to follow-up, the occurrence of outcome event or reaching the end of trial *m*; $\log it^{-1}{\{\mu_{m,k,i}(\hat{\beta})\}}$ and $\log it^{-1}{\{\mu_{m,k,i}^{(b)}(\hat{\beta})\}}$ are the estimated discrete-time hazards at trial visit *k* for patient *i* in trial *m* evaluated at $\hat{\beta}$ using the original dataset and the *b*th bootstrap sample, respectively; $\mathbf{X}_{m,k,i}$ and $\mathbf{X}_{m,k,i}^{(b)}$ are the design vector for the discrete-time hazard MSM at trial visit *k* for patient *i* in trial *m* in the original dataset and in the *b*th bootstrap sample, respectively; $Y_{m,k,i}^{(b)}$ is the observed outcome indicator at trial visit *k* for patient *i* in trial *m* in the bth bootstrap sample.

- (4) For the b^{th} bootstrap sample, estimate the MRD at each trial visit by setting $\hat{\beta}_{\text{LEF}}^{(b)}$ as the MSM parameters.
- (5) Construct the pivot CI using the 2.5th and 97.5th percentiles of the *B* LEF bootstrap estimates of the MRD at each trial visit, as in Section 4.2.

4.3.2 Approach 2: LEF bootstrap for the model parameters for SIPTCWs and the MSM parameters

In the second approach, the Taylor linearisation is applied to the estimating functions of both the models for estimating SIPTCWs and the pooled logistic regression for the MSM (3). Approach 2 should be even more computationally efficient than Approach 1, because it avoids fitting the models for the SIPTCWs to each bootstrap sample. Moreover, Approach 2 could be useful when there are many covariates (relative to the sample size) in the models for the SIPTCWs, in which case ill-conditioned matrices could arise when fitting these models to some of the bootstrap samples.

Because multiple models have to be fitted to obtain the SIPTCWs, we explain the steps for implementing the LEF bootstrap using the model for the denominator term of the stabilised inverse probability of treatment weights (IPTWs, see equation (1) of the Supplementary Materials) given $\overline{A}_{m,k-1} = \overline{1}$ as an illustration. Implementing the LEF bootstrap is analogous for all other models involved in equations (1) and (2) of the Supplementary Materials.

Let $p_{m,k} = \Pr(A_{m,k} = 1 \mid \overline{A}_{m,k-1} = \overline{1}, V, L_{m,k}, E_m = 1, Y_{m,k-1} = 0, C_{m,k-1} = 0)$, the conditional probability that the patient remains treated at trial visit k in trial m given they received treatment up to trial visit k - 1, conditional on their observed variables up to trial visit k. Suppose that a logistic regression model is assumed for $p_{m,k}$,

$$\operatorname{logit}(p_{m,k}) = \mathbf{Z}_{m,k}^{\mathrm{T}} \boldsymbol{\gamma},\tag{7}$$

where $\mathbf{Z}_{m,k}$ is the design vector and $\boldsymbol{\gamma}$ is the regression parameter vector. Note that $\mathbf{Z}_{m,k}$ only contains rows for patients who were always treated in trial m up until the previous trial visit k - 1, i.e. $\overline{A}_{m,k-1} = \overline{1}$. The procedure is as follows.

- (1) Fit the weighted pooled logistic model to the original dataset and obtain the point estimate $\hat{\beta}$ of the MSM parameters, using the estimated weights $w_{m,k,i}$ based on the original dataset.
- (2) Create B bootstrap samples with patients as resampling units, and let $s_i^{(b)}$ denote the number of times that patient *i* is sampled in the *b*th bootstrap sample (b = 1, ..., B). Note that $s_i^{(b)} = 0$ if patient *i* is not sampled in the *b*th bootstrap sample.
- (3) Calculate the LEF bootstrap parameter estimates of the models for estimating SIPTCWs for each bootstrap sample according to (5). For example, the LEF bootstrap estimates $\hat{\gamma}^{(b)}$ of γ in (7) can be obtained by

$$\hat{\gamma}^{(b)} = \hat{\gamma} - \left[\sum_{m=0}^{n_v-1} \sum_{i=1}^n E_{m,i} \sum_{k=0}^{q_{m,i}-1} \mathbb{1}_{\{\overline{A}_{m,k-1,i}=\overline{1}\}} p_{m,k,i}(\hat{\gamma}) \{1 - p_{m,k,i}(\hat{\gamma})\} \mathbf{Z}_{m,k,i} \mathbf{Z}_{m,k,i}^{\mathsf{T}}\right]^{-1} \\ \sum_{m=0}^{n_v-1} \sum_{i=1}^n s_i^{(b)} E_{m,i} \sum_{k=0}^{q_{m,i}-1} \mathbb{1}_{\{\overline{A}_{m,k-1,i}=\overline{1}\}} \mathbf{Z}_{m,k,i} \{A_{m,k,i} - p_{m,k,i}(\hat{\gamma})\},$$
(8)

where $\mathbb{1}_{\{\overline{A}_{m,k-1,i}=\overline{1}\}}$ is the indicator for whether patient *i* has always been treated up to trial visit k-1 in trial *m*, $p_{m,k,i}(\hat{\gamma})$ is the estimated probability of treatment adherence given previous treatment at trial visit *k* for patient *i* in trial *m* evaluated at $\hat{\gamma}$, $\mathbb{Z}_{m,k,i}$ is the corresponding design vector for the logistic regression model (7), and $A_{m,k,i}$ is the observed treatment indicator at trial visit *k* for patient *i* in trial *m*.

- (4) Based on LEF bootstrap parameter estimates for the models for estimating SIPTCWs, calculate a new set of weights $\tilde{w}_{m.k.i}^{(b)}$ for the b^{th} bootstrap sample.
- (5) Construct the pivot CI using Steps (3)-(5) in Approach 1 in Section 4.3.1, replacing $w_{m,k,i}^{(b)}$ with $\tilde{w}_{m,k,i}^{(b)}$ in (6).

4.4 Jackknife

We use jackknife resampling to construct two types of jackknife-based CIs: 1) using a jackknife estimate of the MRD standard error [40], and 2) using the jackknife variance estimator [41, 42] of $\hat{\beta}$. The resampling units are the patients.

4.4.1 Approach 1: Wald-type CI using the jackknife estimate of the MRD standard error

We use the jackknife estimator of the standard error of the MRD estimate and a Normal approximation to obtain CIs as follows:

- 1) Obtain the parameter estimate $\hat{\beta}$ of the MSM in (3) and the MRD estimate $\widehat{MRD}_m(k)$ at each trial visit k in trial m using the method in Section 3.
- 2) For i = 1, ..., n, obtain parameter estimates $\hat{\beta}^{(-i)}$ and $\widehat{MRD}_m^{(-i)}(k)$ using the method in Section 3 after leaving out data from patient *i*.

3) Obtain the jackknife standard error estimate $\widehat{SE}_m^J(k)$ of the MRD at trial visit k in trial m:

$$\widehat{SE}_{m}^{J}(k) = \left[\frac{n-1}{n}\sum_{i=1}^{n} \left(\widehat{MRD}_{m}^{(-i)}(k) - \widehat{MRD}_{m}(k)\right)^{2}\right]^{1/2}$$
(9)

4) Define the lower and upper bounds of the 95% CI for the MRD at trial visit k in trial m, respectively, $\widehat{\text{MRD}}_m(k) - 1.96 \cdot \widehat{\text{SE}}_m^J(k)$ and $\widehat{\text{MRD}}_m(k) + 1.96 \cdot \widehat{\text{SE}}_m^J(k)$.

4.4.2 Approach 2: Multivariate Normal sampling using the jackknife variance estimator of the MSM parameters

We use the jackknife variance estimator [41, 42] of $\hat{\beta}$ to construct simulation-based CIs of the MRD in a manner similar to the sandwich-variance-estimator-based CIs as follows:

- 1) Obtain the parameter estimate $\hat{\beta}$ of the MSM in (3).
- 2) For i = 1, ..., n, obtain parameter estimates $\hat{\beta}^{(-i)}$ using the method in Section 3 after leaving out data from patient *i*.
- 3) Obtain the jackknife variance estimate \hat{V}_J of the MSM parameters:

$$\hat{V}_{J} = \frac{1}{n(n-1)} \sum_{i=1}^{n} (\tilde{\beta}_{i} - \bar{\beta}) (\tilde{\beta}_{i} - \bar{\beta})^{\mathrm{T}}$$
(10)

where
$$\widetilde{\beta}_i = n\hat{\beta} - (n-1)\hat{\beta}^{(-i)}$$
 for $i = 1, ..., n$ and $\bar{\beta} = n^{-1}\sum_{i=1}^n \widetilde{\beta}_i$.

4) Construct a 95% CI by repeating Steps (2)-(4) of Section 4.1 and replacing the sandwich variance matrix estimate $\hat{\Sigma}$ with \hat{V}_{J} .

5 Simulation study

We conducted an extensive simulation study to compare the performance of CIs obtained using the sandwich variance estimator, nonparametric bootstrap, the proposed LEF bootstrap and jackknife methods. For simplicity, we assumed there was no loss to follow-up.

5.1 Study setup

5.1.1 Data generating mechanism

We used the algorithm described in Young and Tchetgen Tchetgen (2014) [43] to simulate data. This algorithm ensure that previous treatments affect time-varying variables (confounders) that are associated with both current treatment and hazard of the outcome event. The data generating mechanism is described in Table 2.

[Table 2 about here.]

5.1.2 Monte Carlo simulation settings

We considered three settings with different outcome event rates, by setting the baseline hazards α_y as -4.7, -3.8 and -3 to allow low (5 - 6.5%), medium (10 - 14%) and high (20 - 25%) percentage of patients experiencing the event during follow-up in the simulated data, respectively. In total, we investigated 81 scenarios for generating the simulated data using the mechanism in Table 2, by considering the combinations of the specifications presented in Table 3. We varied the number of patients, confounding strength of a time-varying confounder and treatment prevalence (i.e., percentage of patients who ever received treatments during follow-up). By varying the intercept term of the treatment model α_a , we could generate a low (25 - 30%), medium (50 - 60%) and high (75 - 80%) treatment prevalence in the simulated data. For each scenario, we generated 1000 simulated datasets.

[Table 3 about here.]

5.1.3 Estimation and inference

For each simulated dataset, we emulated 5 trials (m = 0, ..., 4), with trial 0 including trial visits k = 0, ..., 4, trial 1 including trial visits k = 0, ..., 4 for patients eligible in trial 0. We chose trial 0 patients as the target population because they had the longest follow-up and so we can assess the methods for estimation and inference of the MRDs at later visits.

Correctly specified logistic regression models were fitted to the simulated data to estimate the denominator terms of the stabilised IPTWs in equation (1) of the Supplementary Materials, while the numerator terms were estimated by fitting an intercept-only logistic model stratified by treatments received at the immediately previous visit $A_{t_{i-1}}$.

Then the following weighted pooled logistic model was fitted to the artificially censored data in the five sequential trials to estimate the counterfactual discrete-time hazard:

$$\operatorname{logit}\left\{\Pr\left(Y_{m,k}^{\overline{a}_{k}=\overline{a}}=1 \mid Y_{m,k-1}^{\overline{a}_{k-1}=\overline{a}}=0, X_{1m,0}, X_{2}\right)\right\} = \beta_{0,k} + \beta_{1,k} \cdot a + \beta_{2,k} X_{1,m,0} + \beta_{3,k} X_{2}$$
(11)

where $X_{1,m,0}$ is the value of the time-varying confounder at the baseline of trial m (m = 0, ..., 4) and $\beta_{0,k}$, $\beta_{1,k}$, $\beta_{2,k}$ $\beta_{3,k}$ are regression coefficients that vary by trial visit (k = 0, ..., 4) but are assumed to be the same across trials. Note that we were not able to correctly specify the MSM for counterfactual discrete-time hazard via pooled logistic regression models, due to the non-collapsibility of the logistic model used in the data-generating mechanism [20]. It was to minimise this misspecification (and potential bias caused by it) that we chose the model in (11), which is a rich model that allows the coefficients of treatment and confounders to vary by trial visit.

We applied the methods for constructing 95% CIs of the MRD in Section 4 to each simulated dataset, where we set S = 500 for the CIs based on the sandwich variance estimator and B = 500 for the CIs based on the bootstrap methods. We applied the two jackknife methods only when n = 200, because it would be computationally inefficient relative to bootstrap to use the jackknife CI methods for larger sample sizes. The jackknife method is a linear approximation of the bootstrap [44], and

so we would not expect jackknife CIs to perform any better than bootstrap with larger sample sizes. A pseudo-code algorithm for the simulation study is presented in Section 5 of the Supplementary Materials.

5.1.4 True values

True values of the MRDs for each simulation scenario were obtained by generating data for a very large randomized controlled trial, as proposed by Keogh et al. (2023) [20]. The true marginal risks in trial 0 when all patients were always treated or all patients were never treated were approximated by Kaplan-Meier estimates from two extremely large datasets (n = 1,000,000). For the first dataset, the treatment strategy was set to 'always treated' (by setting $A_{0,k} = 1$ for k = 0, ..., 4). For the second, it was set to 'never treated' (by setting $A_{0,k} = 0$ for k = 0, ..., 4).

5.1.5 Performance measures

Empirical coverage of the CIs was calculated for each trial visit in each simulation scenario. This was done by dividing the number of times that a CI of the MRD contained the true MRD by 1000 minus the number of times there was an error in the CI construction. Such errors include issues with the sandwich variance estimation or jackknife variance estimation that led to non-positive definite variance matrices. We also considered *bias-eliminated CI coverage* to adjust for the impact of bias in the coverage results [45]. This involved calculating the proportion of the 1000 CIs that contained the sample mean of the 1000 MRD estimates for each scenario.

Morris et al (2019) [45] state four potential reasons for CI under- or over-coverage when examining simulation results: (i) MRD estimation bias, (ii) the standard error estimates from a CI method underestimate the empirical standard deviation (SD) of the MRD estimator, (iii) the distribution of the MRD estimates is not normal and CIs have been constructed assuming normality, and (iv) the standard error estimates from a CI method are too variable. Therefore, for each simulation scenario, we calculated the *empirical bias* of the MRD estimates at each trial visit to check reason (i) for CI under-coverage. For each CI method, we calculated the SD of the MRD estimates (from resampling), denoted as \widehat{SE} . This provided us with 1,000 standard error estimates for each CI method. We then computed $\frac{\widehat{SE}}{SD_{MRD}}$, the *ratio of standard error estimate for each CI method to the SD of the MRD empirical distribution* SD_{MRD} , where the SD_{MRD} was obtained by taking the SD of the 1000 MRD point estimates across simulations. We referred to this ratio as the 'Standard Error (SE) ratio'. The summary statistics of the SE ratio across 1000 simulations would allow us to assess reasons (ii) and (iv) for potential CI under-coverage or over-coverage.

We recorded the number of times that each CI method encountered an error (a *'construction failure'*). We also calculated the *Monte Carlo standard error* of the empirical coverage (due to using a finite number of simulated datasets) [45]:

$$SE_{MC} = \sqrt{\frac{Coverage(1 - Coverage)}{n_{sim}}},$$
(12)

where Coverage is the empirical coverage and n_{sim} is the number of simulations performed ($n_{sim} = 1000$ in our case).

Finally, we reported the relative computation time that it took to construct CIs based on nonparametric bootstrap, LEF bootstrap and jackknife compared to CIs based on the sandwich variance estimator.

5.1.6 Computational resources

The simulations were conducted using R (version 4.1.3) [46]. All R scripts are available at https://github.com/ juliettelimozin/Multiple-trial-emulation-IPTW-MSM-CIs. Point estimation and CI construction based on the sandwich variance estimator were performed using the R package TrialEmulation [37] (version 0.0.3.9), and some of the key functions in the R package are summarised in Section 5 of the Supplementary Materials. We used packages doParallel and doRNG to parallelise the simulation, which took 12 hours to finish by using 67 cores of the University of Cambridge high-performance computing cluster.

5.2 Results

In this section, we focus on the discussion of the results in low event rate scenarios; results for medium and high event rate scenarios can be found in Section 6 of the Supplementary Materials. The reason for this focus is two-fold: 1) The HERS data example had low event rates; 2) the CI methods performed the worst in low event rate scenarios and yet we still observed interesting patterns for their relative performance, which were not drastically different from those in medium and high event rate scenarios.

Figure 1 shows the empirical coverage rates of the CIs when the event rate was low; see Figures 2 and 3 of the Supplementary Materials for results with medium and high event rates. Differences between these coverage rates and the corresponding bias-eliminated coverage rates were negligible (see Figures 4, 5 and 6 of the Supplementary Materials).

We will initially examine the bias of the MRD estimates, followed by the SE ratio results for the CI methods, to explain the under-coverage or over-coverage of the CIs and the relative performance of these CI methods in various simulation scenarios. Afterwards, we will discuss computation time for the CI methods. Results for Monte Carlo standard errors of the CI coverage estimates and CI construction failure rates can be found in Section 6.6 and 6.7 of the Supplementary Materials. Since we observe very little difference in the performance of the two LEF bootstrap CI methods, we will refer to them as one when discussing the results. We refer to the CIs constructed using the sandwich variance estimator as 'Sandwich CIs', those using Approach 1 from jackknife resampling as 'Jackknife Wald CIs' and those using Approach 2 as 'Jackknife Multivariate Normal (MVN) CIs'.

[Figure 1 about here.]

5.2.1 Empirical bias and its impact on CI coverage

Figure 2 presents the empirical biases of the MRD estimates.

Minimal biases were observed at *earlier visits* (k < 2), which approached zero as sample sizes increased. The increasing absolute bias at *later visits* (k > 2) could be explained by the increasing data sparsity and treatment arm imbalances at later

visits. Very few events occurred after trial visit 2 in most scenarios, even in those with large sample sizes (n = 5000) (see Table 3 of Supplementary Materials for an example).

The absolute biases in *low or high treatment prevalence* scenarios were larger than those in medium treatment prevalence scenarios. This likely stemmed from data sparsity issues at later trial visits that were aggravated by treatment arm imbalance caused by low or high treatment prevalence. Table 1 of the Supplementary Materials shows an example of this imbalance.

Confounding strength had a negligible effect on absolute bias, perhaps because the specified values of confounding strength α_c had relatively small influences on the data generating mechanism.

Increasing the outcome event rate tended to reduce absolute bias, because it reduced data sparsity.

These bias results explain the general trends of CI coverage in Figure 1. As the sample size increased, the CI coverage at earlier visit approached the nominal 95% level, which was not surprising given that all the methods rely on asymptotic approximations. The increasing absolute bias at *later visits* (k > 2) coincided with the deterioration in CI coverage that we observed across all simulation scenarios at later visits (reason (i) of under-coverage according to Morris et al. [45]).

[Figure 2 about here.]

In scenarios with low treatment prevalence ($\alpha_a = -1$), CI coverage did not achieve the nominal 95% level at later visits (k > 2) even with larger sample sizes. Similarly, in scenarios with high treatment prevalence ($\alpha_a = 1$), nominal coverage was rarely achieved, except at the baseline visit (k = 0), and coverage decayed considerably at later visits for Sandwich CIs, nonparametric and LEF bootstrap CIs.

We observed minimal impact of confounding strength on CI coverage. Increasing the event rate improved the CI coverage for all methods, as shown in Figures 2 and 3 of the Supplementary Materials.

The empirical SD and the root-Mean Squared Error (MSE) of the MRD estimates largely followed the patterns of the bias (see Figures 7 and 8 of the Supplementary Materials): scenarios with larger biases also exhibited larger SDs and MSEs.

5.2.2 SE ratio and its impact on CI coverage

Figures 3 and 4 present the summary statistics of the SE ratio, $\frac{\widehat{SE}}{\overline{SD}_{MRD}}$, for each CI method in scenarios with low event rates and small sample size (n = 200); see Figures 9–15 of the Supplementary Materials for scenarios with low event rates and moderate/large sample sizes and for scenarios with medium and high event rates.

[Figure 3 about here.]

We found that the SE ratio results largely explained the differences in CI coverage of the various CI methods. The comparative performance of the CI methods in terms of coverage generally followed the patterns of the SE ratios: when the average SE ratios were above 1, we observed over-coverage; when the average SE ratios were about 1, we observed close to nominal coverage; when the average SE ratios were below 1, we observed under-coverage. Higher variability of the SE ratios also coincided with lower CI coverage. Notably, in scenarios with *high event rate, large sample size, medium treatment prevalence*

and weak confounding, all CI methods achieved nominal coverage, which corresponded to all CI methods having SE ratios close to 1 on average and with low variability.

Low event rate and small sample size scenarios From Figure 3, we can see that the SE ratios for nonparametric bootstrap CIs were on average lower than 1 at later visits, and they were also more variable, especially with *high treatment prevalence*. This is consistent with the coverage results in Figure 1, where we expect nonparametric bootstrap CIs to have low coverage if the variability of the MRD estimator was underestimated and the variability estimates were highly variable across simulations [45]. The nonparametric bootstrap CIs had lower coverage compared to LEF bootstrap CIs in scenarios with low/medium treatment prevalence, and lower coverage than Sandwich CIs when treatment prevalence was high. This performance is mirrored in the SE ratio results for nonparametric bootstrap CIs in such scenarios. It was likely that the data sparsity issues at later visits increased the instability of parameter estimation in bootstrap samples and thus resulted in the lower SE ratios and large variability of SE ratios for nonparametric bootstrap CIs. In contrast, LEF bootstrap reduced instability of parameter estimation in bootstrap samples at later visits. Similar findings for nonparametric bootstrap CIs were observed by Austin (2022) [26].

In Figure 3, the SE ratios for jackknife Wald CIs were also lower than 1 at later visits, but in low and high treatment prevalence scenarios, they were less variable compared to those for nonparametric bootstrap CIs, which might partly explain the better coverage of jackknife Wald CIs in these scenarios. However, in Figure 4, the SE ratios for jackknife MVN CIs were much larger than 1 in all scenarios with small sample sizes, which may explain the over-coverage or closer-to-nominal coverage for jackknife MVN CIs in some scenarios.

In Figure 3, the SE ratios for LEF bootstrap CIs and Sandwich CIs were larger than 1 at *early visits* (k < 2), but they gradually dropped below 1 at later visits. When the *treatment prevalence was high* ($\alpha_a = 1$), their SE ratios were much lower but less variable than those of nonparametric bootstrap CIs at the later visits. LEF bootstrap CIs also provided better coverage than Sandwich CIs at later visits in small sample size scenarios, possibly because the SE ratios for LEF bootstrap CIs were on average closer to 1 or less variable than the Sandwich CIs' SE ratios. In such scenarios, Sandwich CIs might have suffered from finite-sample bias of variance matrix estimation that affected the multivariate normal sampling for the MRD estimation, as well as the construction failures due to non-positive definite variance matrices (see Table 13 of the Supplementary Materials).

[Figure 4 about here.]

Low event rate and medium/large sample size scenarios In Figure 9 of the Supplementary Materials, with larger sample sizes (n = 1000, 5000), the SE ratio results for all CI methods were improved in low/medium treatment prevalence scenarios, which was reflected correspondingly by the better coverage. The SE ratios of the LEF bootstrap CIs were above 1 at most visits in low/medium treatment prevalence scenarios, which could explain some of the CI over-coverage we observed and the better coverage compared with Sandwich CIs. With high treatment prevalence, the SE ratios of the LEF bootstrap sample at later visits approached to 1 on average as sample sizes increased, but they became more variable as well. This might explain the corresponding decreased coverage of LEF bootstrap CIs, which was now similar to the coverage of nonparametric

bootstrap CIs. Similar patterns in high treatment prevalence scenarios were also observed for the SE ratios of Sandwich CIs. However, they were slightly less variable than those of LEF bootstrap CIs and closer to 1 than those of nonparametric bootstrap CIs, which might be due to the much reduced number of construction failures for Sandwich CIs in large sample size and high treatment prevalence scenarios. Overall, this resulted in better coverage of of Sandwich CIs in these scenarios.

Medium/high event rate scenarios From Figures 10–15 in the Supplementary Materials, increasing the outcome event rate also improved the SE ratio results for all CI methods, with the SE ratios approaching 1 and becoming less variable. This is consistent with the coverage results in Figures 2–3 in the Supplementary Materials, where an increase of outcome event rate resulted in the various CI methods converging to similar closer-to-nominal coverage. However, in scenarios with large sample sizes and low or high treatment prevalence, we still observed SE ratios to be lower than 1 and highly variable at later visits. Together with the larger empirical bias, this could explain the low coverage at later visits for all CI methods in these scenarios.

With increased event rates, we observed that differences in CI coverage among the methods were primarily due to SE ratio variability. In most scenarios with medium/high event rates and medium/large sample sizes, the average SE ratios of Sandwich CI and LEF bootstrap CIs were very similar but the SE ratios of Sandwich CIs tended to be less variable, which might lead to their better coverage. With medium/large sample sizes, nonparametric bootstrap CIs and LEF bootstrap CIs had similar SE ratios, resulting in similar coverage, whereas with small sample sizes, the SE ratios of nonparametric bootstrap CIs tended to be much more variable than those for LEF bootstrap CIs, leading to worse coverage.

Confounding strength scenarios Similarly to the empirical bias results, the confounding strength appeared to have minimal impact on the SE ratio results. This also translated to minimal impact of confounding strength on CI coverage.

5.2.3 Computation time

Table 4 summarises the average computation time (across 1000 simulated data sets and the scenarios of treatment prevalence and confounding strength) for constructing a CI of the MRD using each method, relative to the time for constructing Sandwich CI. On average, nonparametric bootstrap CIs took about 3 to 8 times longer to compute than Sandwich CIs. The computation time increased exponentially as sample sizes increased. LEF bootstrap CIs, using both Approaches 1 and 2, took about 1.6 to 2.5 times longer to compute compared to Sandwich CIs. LEF bootstrap CIs were not as affected by sample sizes in terms of computation time compared to nonparametric bootstrap CIs.

For small sample sizes (n = 200), jackknife Wald CIs had very similar computation times to LEF bootstrap CIs. Jackknife MVN CIs took 3 times longer to construct compared to Sandwich CIs, most likely because the former method required two sampling steps: the jackknife resampling step and the MVN sampling step, while Sandwich CIs only involved the MVN sampling step.

The large gain in computational efficiency through LEF bootstrap is very much of interest; with large sample sizes (n = 5000), LEF bootstrap was on average 3 times faster than nonparametric bootstrap. However, the sandwich variance estimator-

based method remains the fastest for CI construction, especially if it is not possible to parallelise the computing of the bootstrap-based CIs.

[Table 4 about here.]

5.2.4 Summary

Our simulation results suggest that LEF bootstrap CIs provided better coverage compared to Sandwich CIs in scenarios with small/medium sample sizes, low/medium outcome event rates and low/medium treatment prevalence. This might be attributed to the finite sample bias of the sandwich variance estimator and high frequency of the construction failure of Sandwich CIs in such scenarios. The performance of nonparametric bootstrap CIs was considerably affected by treatment arm imbalance and data sparsity, particularly in scenarios with low event rates and small/moderate sample sizes. In these scenarios, the LEF bootstrap method not only performed better but was also more computationally efficient than nonparametric bootstrap. While jackknife Wald CIs achieved nominal coverage for small sample sizes and low treatment prevalence, they were sensitive to treatment prevalence. Due to data sparsity and finite-sample bias, all methods performed poorly when treatment prevalence was high, and jackknife MVN CIs faced numerous construction failures, making them impractical for use.

Since STE is particularly useful for data scenarios with small numbers of patients initiating treatments at any given time (low treatment prevalence) and with low event rates, LEF bootstrap offers a useful alternative to the sandwich variance estimator and the nonparametric bootstrap for CI construction, especially in small/medium sample sizes. Although jackknife Wald CIs also provided good coverage, they become computationally inefficient as the number of patients exceeds the number of bootstrap samples. For large sample sizes and medium/high event rates, Sandwich CIs has the advantage of being computationally more efficient than the bootstrap CI methods. Overall, our investigation underscores the importance of considering sample size, outcome event rate, and treatment prevalence when selecting a CI construction method in STE.

6 Application to the HERS data

In this section, we applied the methods described in Sections 3–4 to the HERS data. The treatment process for the denominator term of the stabilised IPTWs was modelled by two logistic regressions stratified by treatment received at the immediately previous visit $A_{t_{j-1}}$ (j = 1, ..., 4). We included the following covariates: CD4 count (after square root transformation and standardization) and HIV viral load (after \log_{10} transformation and standardization) measured at the previous two visits (since HAART treatment was a self-reported status between the last visit and the current visit), HIV symptoms at the previous visit, ethnicity (Caucasian, Black, other) and study sites. The numerator term of the stabilised IPTWs was estimated as the marginal probability of receiving HAART in the stratum defined by previous treatment $A_{t_{j-1}}$.

Similarly, the censoring process for the denominator term of the stabilised inverse probability of censoring weights (IPCWs, see equation (2) of the Supplementary Materials) was modelled by two logistic regressions stratified by the previous treatment $A_{t_{i-1}}$. The following covariates were included: CD4 count, HIV viral load and HIV symptoms measured at the current

and previous visits, ethnicity and study sites. The numerator term of the stabilised IPCWs was estimated by the marginal probabilities of remaining in the HERS cohort, stratified by the previous treatment A_{ti-1} .

[Table 5 about here.]

The pooled logistic regression for the MSM included an intercept term, main effect of treatment, main effects of CD4 count and HIV viral load at previous two visits before the trial baseline, main effects of ethnicity and study sites, and the interaction between treatment and CD4 count at the visit before trial baseline. A summary of the fitted MSM is provided in Table 5.

We used 500 bootstrap samples for Nonparametric and LEF bootstrap CIs, and drew a sample of size S = 500 of MSM parameters for constructing Sandwich CIs.

[Figure 5 about here.]

Figure 5 presents the estimated MRD, which is the difference in risk of all-cause mortality when all patients eligible to trial 0 adhere to the treatment strategies assigned (HAART vs. no HAART). Figure 5 also includes 95% CIs of the MRD obtained by the four methods described in Section 4. We note that the results are not statistically significant given that all four CIs include zero.

7 Discussion

In this article, we focused on the application of STE to estimate and make inferences about the per-protocol effect of treatments on a survival outcome in terms of counterfactual MRDs over time. We conducted a simulation study to compare the relative performance of four CI construction methods for the MRD, based on the sandwich variance estimator, nonparametric bootstrap, LEF bootstrap (which previously had not been extended to STE) and jackknife resampling. In scenarios with small/moderate sample sizes, low event rates and low treatment prevalence, we observed relatively better coverage for LEF bootstrap CIs than for nonparametric bootstrap and Sandwich CIs. These results align with previous findings on the limitations of the sandwich variance estimator when the sample size is small [47, 48]. Since STE is particularly useful in scenarios with small sample sizes, low event rates and low treatment prevalence, the LEF bootstrap offers a valuable alternative to the sandwich variance estimator and the nonparametric bootstrap for constructing CIs of the MRD. With large sample sizes and medium/high event rates, Sandwich CIs exhibited relatively better performance in our simulation results also highlighted how data sparsity issues which are inherent when implementing STE can greatly affect CI performance, meaning that one should carefully consider features of their data when choosing a CI method.

Although dependent censoring was not included in the data generating mechanism of our simulation study, we expect that the relative performance of CIs constructed using LEF bootstrap and the sandwich variance estimator observed in our simulation study would also hold if there were dependent censoring and IPCWs were used to handle it. Inference would still face the same issues, but with the additional uncertainty caused by the estimation of IPCWs and possible exacerbation of the finite-sample bias as a result of loss of information.

We primarily focused on pooled logistic regressions for fitting MSMs and did not explore alternative survival time models, such as additive hazards models [20]. Additive hazard models can be used in moderate-to-high event rates settings, while in low event rate settings they might result in negative hazard estimates. Inference procedures for STE based on additive hazard models warrant further research.

We have used parametric models for estimation of the SIPTCWs. Recent developments in nonparametric data-adaptive methods have led to their widespread use in biomedical research. This is partly because these models have become more accessible due to increased automation in their implementation across programming languages. Because the consistency of the weighted estimators of the MSM parameters relies on correct specification of treatment and censoring models, data-adaptive methods are attractive. However, the subsequent inference can be challenging [49, 50, 51, 52, 53, 54].

Throughout this article, it was assumed that there were no unmeasured confounders. However, in practice, this assumption is unlikely to hold, as it is challenging to identify and measure all potential confounders in observational databases. Instrumental variable approaches and sensitivity analysis have been proposed to deal with such unmeasured confounding for point treatments. Recently, Tan (2023) proposed a sensitivity analysis approach in general longitudinal settings [55]. In the specific setting of STE, sensitivity analysis methods for unmeasured confounding warrant further research.

Acknowledgements

The authors would like to thank Dr Brian Tom and Dr Pantelis Samartsidis for helpful comments and suggestions. Data from the HERS were collected under grant U64-CCU10675 from the U.S. Centers for Disease Control and Prevention. This work is supported by the U.K. Medical Research Council [grants MC_UU_00002/15, MC_UU_00040/03 and MC_UU_00040/05] and the MRC Biostatistics Unit Core Studentship.

References

- Hernán MA and Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1. *American Journal of Epidemiology* 2016; 183(8): 758–764. doi:10.1093/aje/kwv254.
- [2] Hansford HJ, Cashin AG, Jones MD et al. Reporting of Observational Studies Explicitly Aiming to Emulate Randomized Trials: A Systematic Review. JAMA network open 2023; 6(9): e2336023. doi:10.1001/jamanetworkopen.2023.36023.
- [3] Matthews AA, Szummer K, Dahabreh IJ et al. Comparing effect estimates in randomized trials and observational studies from the same population: An application to percutaneous coronary intervention. *Journal of the American Heart Association* 2021; 10(11). doi:10.1101/2021.02.01.21250739.
- [4] Hernán MA, Wang W and Leaf DE. Target Trial Emulation. JAMA 2022; 328(24): 2446. doi:10.1001/jama.2022.21383.
- [5] Matthews AA, Danaei G, Islam N et al. Target trial emulation: applying principles of randomised trials to observational studies. *BMJ* 2022; : e071108doi:10.1136/bmj-2022-071108.

- [6] Maringe C, Benitez Majano S, Exarchakou A et al. Reflection on modern methods: Trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data. *International Journal of Epidemiology* 2020; 49(5). doi:10.1093/ije/dyaa057.
- [7] Robins JM, Hernán MA and Brumback B. Marginal Structural Models and Causal Inference in Epidemiology. *Epidemiology* 2000; 11(5): 550–560. doi:10.1097/00001648-200009000-00011.
- [8] Robins JM and Finkelstein DM. Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log-Rank Tests. *Biometrics* 2000; 56(3): 779–788. doi:10.1111/j.0006-341X.2000.00779.x.
- [9] Hernán MA, Brumback B and Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. *Epidemiology (Cambridge, Mass)* 2000; 11(5): 561–70. doi:10.1097/00001648-200009000-00012.
- [10] Hernán MA, Brumback B and Robins JM. Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments. *Journal of the American Statistical Association* 2001; 96(454): 440–448. doi:10.1198/016214501753168154.
- [11] Cain LE and Cole SR. Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death. *Statistics in Medicine* 2009; 28(12): 1725–1738. doi:10.1002/sim.3585.
- [12] Seaman SR and White IR. Review of inverse probability weighting for dealing with missing data. *Statistical Methods in Medical Research* 2013; 22(3): 278–295. doi:10.1177/0962280210395740.
- [13] Clare PJ, Dobbins TA and Mattick RP. Causal models adjusting for time-varying confounding—a systematic review of the literature. *International Journal of Epidemiology* 2019; 48(1): 254–265. doi:10.1093/ije/dyy218.
- [14] Hernán MA, Alonso A, Logan R et al. Observational Studies Analyzed Like Randomized Experiments. *Epidemiology* 2008; 19(6): 766–779. doi:10.1097/EDE.0b013e3181875e61.
- [15] Daniel R, Cousens S, De Stavola B et al. Methods for dealing with time-dependent confounding. *Statistics in Medicine* 2013; 32(9): 1584–1618. doi:10.1002/sim.5686.
- [16] Murray EJ, Caniglia EC and Petito LC. Causal survival analysis: A guide to estimating intention-to-treat and perprotocol effects from randomized clinical trials with non-adherence. *Research Methods in Medicine & Health Sciences* 2021; 2(1): 39–49. doi:10.1177/2632084320961043.
- [17] D'Agostino RB, Lee ML, Belanger AJ et al. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. *Statistics in Medicine* 1990; 9(12): 1501–1515. doi:10.1002/sim.4780091214.
- [18] Hernán MA. The Hazards of Hazard Ratios. Epidemiology 2010; 21(1): 13-15. doi:10.1097/EDE.0b013e3181c1ea43.
- [19] Buchanan AL, Hudgens MG, Cole SR et al. Worth the Weight: Using Inverse Probability Weighted Cox Models in AIDS Research. AIDS Research and Human Retroviruses 2014; 30(12): 1170–1177. doi:10.1089/aid.2014.0037.

- [20] Keogh RH, Gran JM, Seaman SR et al. Causal inference in survival analysis using longitudinal observational data: Sequential trials and marginal structural models. *Statistics in Medicine* 2023; 42(13): 2191–2225. doi:10.1002/sim.9718.
- [21] Gran JM, Røysland K, Wolbers M et al. A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. *Statistics in Medicine* 2010; 29(26): 2757–2768. doi:10.1002/sim.4048.
- [22] Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. *Statistics in Medicine* 2016; 35(30): 5642–5655. doi:10.1002/sim.7084.
- [23] Shu D, Young JG, Toh S et al. Variance estimation in inverse probability weighted Cox models. *Biometrics* 2021; 77(3): 1101–1117. doi:10.1111/biom.13332.
- [24] Lin DY and Wei LJ. The Robust Inference for the Cox Proportional Hazards Model. *Journal of the American Statistical Association* 1989; 84(408): 1074–1078. doi:10.1080/01621459.1989.10478874.
- [25] Enders D, Engel S, Linder R et al. Robust versus consistent variance estimators in marginal structural Cox models. *Statistics in Medicine* 2018; 37(24): 3455–3470. doi:10.1002/sim.7823.
- [26] Austin PC. Bootstrap vs asymptotic variance estimation when using propensity score weighting with continuous and binary outcomes. *Statistics in Medicine* 2022; doi:10.1002/sim.9519.
- [27] Mao H, Li L, Yang W et al. On the propensity score weighting analysis with survival outcome: Estimands, estimation, and inference. *Statistics in Medicine* 2018; 37(26): 3745–3763. doi:10.1002/sim.7839.
- [28] Seaman SR and Keogh RH. Simulating data from marginal structural models for a survival time outcome, 2023.
- [29] Serdarevic M, Cvitanovich M, MacDonald BR et al. Emergency Department Bridge Model and Health Services Use Among Patients With Opioid Use Disorder. Annals of Emergency Medicine 2023; 82(6): 694–704. doi:10.1016/j.annemergmed.2023.06.014.
- [30] Virtanen S, Lagerberg T, Takami Lageborn C et al. Antidepressant Use and Risk of Manic Episodes in Children and Adolescents With Unipolar Depression. JAMA Psychiatry 2024; 81(1): 25–33. doi:10.1001/jamapsychiatry.2023.3555.
- [31] Danaei G, Rodríguez LAG, Cantero OF et al. Observational data for comparative effectiveness research: An emulation of randomised trials of statins and primary prevention of coronary heart disease. *Statistical Methods in Medical Research* 2013; 22(1): 70–96. doi:10.1177/0962280211403603.
- [32] Hu F and Kalbfleisch JD. The estimating function bootstrap. *Canadian Journal of Statistics* 2000; 28(3): 449–481. doi:10.2307/3315958.
- [33] Rao JNK and Tausi M. Estimating Function Jackknife Variance Estimators Under Stratified Multistage Sampling. Communications in Statistics - Theory and Methods 2004; 33(9): 2087–2095. doi:10.1081/STA-200026577.
- [34] Binder D, Kovacevic M and Roberts G. Design-based methods for survey data: alternative uses of estimating functions. In *Proceedings of the Survey Research Methods Section*. American Research Association, 2004. pp. 3301–3312.

- [35] Ko H, Hogan JW and Mayer KH. Estimating causal treatment effects from longitudinal HIV natural history studies using marginal structural models. *Biometrics* 2003; 59(1): 152–162. doi:10.1111/1541-0420.00018.
- [36] Yiu S and Su L. Joint calibrated estimation of inverse probability of treatment and censoring weights for marginal structural models. *Biometrics* 2022; 78(1): 115–127. doi:10.1111/biom.13411.
- [37] Rezvani R, Gravestock I and Su L. TrialEmulation: Causal Analysis of Observational Time-to-Event Data, 2023.
- [38] Mandel M. Simulation-Based Confidence Intervals for Functions With Complicated Derivatives. *The American Statistician* 2013; 67(2): 76–81. doi:10.1080/00031305.2013.783880.
- [39] Carpenter J and Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. *Statistics in Medicine* 2000; 19(9): 1141–1164. doi:10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F.
- [40] Tibshirani BE R J. An Introduction to the Bootstrap. New York: Chapman and Hall/CRC, 1994. ISBN 9780429246593. doi:10.1201/9780429246593.
- [41] Lipsitz SR, Laird NM and Harrington DP. Using the jackknife to estimate the variance of regression estimators from repeated measures studies. *Communications in Statistics - Theory and Methods* 1990; doi:10.1080/03610929008830234.
- [42] Friedl H and Stampfer E. Jackknife Resampling. In *Encyclopedia of Environmetrics*. John Wiley & Sons, Ltd. ISBN 978-0-470-05733-9, 2006. doi:10.1002/9780470057339.vaj001.
- [43] Young JG and Tchetgen Tchetgen EJ. Simulation from a known Cox MSM using standard parametric models for the g-formula. *Statistics in Medicine* 2014; 33(6): 1001–1014. doi:10.1002/sim.5994.
- [44] Efron B. Bootstrap Methods: Another Look at the Jackknife. The Annals of Statistics 1979; 7(1): 1–26. doi:10.1214/aos/1176344552.
- [45] Morris TP, White IR and Crowther MJ. Using simulation studies to evaluate statistical methods. *Statistics in Medicine* 2019; 38(11): 2074–2102. doi:10.1002/sim.8086.
- [46] R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2023.
- [47] Pan W and Wall MM. Small-sample adjustments in using the sandwich variance estimator in generalized estimating equations. *Statistics in Medicine* 2002; 21(10): 1429–1441. doi:10.1002/sim.1142.
- [48] Rogers P and Stoner J. Assessment of a Modified Sandwich Estimator for Generalized Estimating Equations with Application to Opioid Poisoning in MIMIC-IV ICU Patients. *Stats* 2021; 4(3): 650–664. doi:10.3390/stats4030039.
- [49] Schuler MS and Rose S. Targeted Maximum Likelihood Estimation for Causal Inference in Observational Studies. *American Journal of Epidemiology* 2017; 185(1): 65–73. doi:10.1093/aje/kww165.
- [50] Chernozhukov V, Chetverikov D, Demirer M et al. Double/Debiased Machine Learning for Treatment and Causal Parameters, 2017. doi:10.48550/arXiv.1608.00060.

- [51] Cai W and van der Laan M. Nonparametric bootstrap inference for the targeted highly adaptive least absolute shrinkage and selection operator (LASSO) estimator. *The International Journal of Biostatistics* 2020; 16(2). doi:10.1515/ijb-2017-0070.
- [52] Petersen M, Schwab J, Gruber S et al. Targeted Maximum Likelihood Estimation for Dynamic and Static Longitudinal Marginal Structural Working Models. *Journal of Causal Inference* 2014; 2(2): 147–185. doi:10.1515/jci-2013-0007.
- [53] Zheng W, Petersen M and Laan MJvd. Doubly Robust and Efficient Estimation of Marginal Structural Models for the Hazard Function. *The International Journal of Biostatistics* 2016; 12(1): 233–252. doi:10.1515/ijb-2015-0036.
- [54] Ertefaie A, Hejazi NS and van der Laan MJ. Nonparametric inverse probability weighted estimators based on the highly adaptive lasso. *Biometrics* 2023; 79(2): 1029–1041. doi:10.1111/biom.13719.
- [55] Tan Z. Sensitivity models and bounds under sequential unmeasured confounding in longitudinal studies, 2023. doi:10.48550/arXiv.2308.15725.

List of Figures

- 1 Empirical coverage of the CIs in the scenarios with **low event rates**. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of jackknife resampling; jackknife MVN: CIs constructed by applying Approach 2 of jackknife resampling; Sandwich: CIs based on the sandwich variance estimator. Note that the results for applying Approachs 1 and 2 of LEF bootstrap were very similar so that the purple and green lines overlapped. 29
- 3 Ratio of the estimated standard error to empirical standard deviation of the MRD estimator (SE ratio) in low event rate and small sample size scenarios. The dots represent the averages of the ratio, with the bottom and top of the bar being the 1st and 3rd quartile of this ratio, respectively. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of jackknife resampling; Sandwich: CIs based on the sandwich variance estimator.
- 5 Estimates and 95% CIs of the MRD of all-cause mortality under HAART treatment strategy and the non-HAART strategy for patients enrolled in the first emulated trial (trial 0) of the HERS data. Nonparametric Boot.: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Sandwich: CIs based on the sandwich variance estimator.











Figure 3: Ratio of the estimated standard error to empirical standard deviation of the MRD estimator (SE ratio) in **low event rate and small sample size scenarios**. The dots represent the averages of the ratio, with the bottom and top of the bar being the 1st and 3rd quartile of this ratio, respectively. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of jackknife resampling; Sandwich: CIs based on the sandwich variance estimator.



Figure 4: Ratio of the estimated standard error to empirical standard deviation of the MRD estimator (SE ratio) in **low event rate and small sample size scenarios**. The dots represent the averages of the ratio, with the bottom and top of the bar being the 1st and 3rd quartile of this ratio respectively. Jackknife MVN: CIs constructed by applying Approach 2 of jackknife resampling.



Figure 5: Estimates and 95% CIs of the MRD of all-cause mortality under HAART treatment strategy and the non-HAART strategy for patients enrolled in the first emulated trial (trial 0) of the HERS data. Nonparametric Boot.: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Sandwich: CIs based on the sandwich variance estimator.

List of Tables

1	Data tabulation of the HERS data prepared for a per-protocol analysis in sequential trial emulation. The numbers in a column represent the number of patients enrolled in an emulated sequential trial by their assigned treatment strategies, outcome and censoring status by the end of the emulated trial. Treatment: assigned treatment strategies; 0, never treated with HAART; 1, always treated with HAART. Outcome: indicator of all-cause mortality. Censoring: indicator of censoring due to loss to follow-up	35
2	Summary of data generating mechanism of the simulation study.	36
3	Summary of the specifications for the 81 scenarios considered in the simulations.	37
4	Summary of average computation time of the CI construction methods in simulations with the sandwich- variance-estimator-based CIs as the reference. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of jackknife resampling; Jackknife MVN: CIs constructed by applying Approach 2 of jackknife resampling; Sandwich: CIs based on the sandwich variance estimator.	38
5	Results for the fitted MSM for the sequentially emulated trials using the HERS data. Robust standard error: standard errors based on the sandwich variance estimate.	39

Table 1: Data tabulation of the HERS data prepared for a per-protocol analysis in sequential trial emulation. The numbers in a column represent the number of patients enrolled in an emulated sequential trial by their assigned treatment strategies, outcome and censoring status by the end of the emulated trial. Treatment: assigned treatment strategies; 0, never treated with HAART; 1, always treated with HAART. Outcome: indicator of all-cause mortality. Censoring: indicator of censoring due to loss to follow-up.

		Trial	0	1	2	3	4
Treatment	Outcome	Censoring					
0	0	0	390	315	250	175	155
		1	14	16	15	49	0
	1	0	11	8	5	5	4
1	0	0	73	54	49	25	19
		1	1	5	0	1	0
	1	0	2	3	1	0	1
		Total eligible in trial	491	401	320	255	179

Data simulation setting specifications	n: number of patients $n_v = 5$: number of visits $t_j = 0,, n_v - 1$: visit time for visit j α_a : intercept in the treatment model, representing the baseline rate of treat- ment initiation α_c : coefficient that describes the strength of confounding due to time-varying variable X_{1,t_j} α_y : intercept term in the discrete-time hazard model, representing the base- line hazard
Time-varying confounder Time-invariant confounder	$X_{1,t_j} \sim N(Z_{t_j} - 0.3A_{t_{j-1}}, 1)$, where $A_{t_{-1}} \equiv 0$ and $Z_{t_j} \sim N(0, 1)$. $X_2 \sim N(0, 1)$.
Treatment	$\begin{split} \log & \text{it}\{\Pr(A_{t_j} = 1 \mid A_{t_{j-1}}, X_{1,t_j}, X_2, Y_{t_{j-1}} = 0)\} \\ &= \alpha_a + 0.05A_{t_{j-1}} + \alpha_c X_{1,t_j} + 0.2X_2, \text{ where } Y_{t_{-1}} \equiv 0. \end{split}$
Discrete-time hazard of the outcome event	$logit{Pr(Y_{t_j} = 1 A_{t_j}, X_{1,t_j}, X_2, Y_{t_{j-1}} = 0)} = \alpha_y - 0.5A_{t_j} + \alpha_c X_{1,t_j} + X_2.$
Trial Eligibility	$E_{t_j} = 1$ if patient has not received treatment before t_j and has not experienced the outcome event before t_j ; $E_{t_j} = 0$ otherwise

Table 2: Summary of data generating mechanism of the simulation study.
Outcome event rate	Sample size	Confounding strength	Treatment prevalence
Low: $\alpha_y = -4.7$	Small: $n = 200$	$\begin{array}{l} \alpha_c = 0.1 \\ \alpha_c = 0.5 \\ \alpha_c = 0.9 \end{array}$	Low: $\alpha_a = -1$
Medium: $\alpha_y = -3.8$	Medium: $n = 1000$		Medium: $\alpha_a = 0$
High: $\alpha_y = -3$	Large: $n = 5000$		High: $\alpha_a = 1$

Table 3: Summary of the specifications for the 81 scenarios considered in the simulations.

Table 4: Summary of average computation time of the CI construction methods in simulations with the sandwich-varianceestimator-based CIs as the reference. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of jackknife resampling; Jackknife MVN: CIs constructed by applying Approach 2 of jackknife resampling; Sandwich: CIs based on the sandwich variance estimator.

		Bootstrap	LEF	LEF	Jackknife	Jackknife	Sandwich
Outcome event rate	Sample size		outcome	both	Wald	MVN	
Low	200	2.94	1.83	1.62	1.78	3.00	1
	1000	4.28	1.92	1.74			1
	5000	8.39	2.66	2.50			1
Medium	200	2.99	1.88	1.66	1.81	3.04	1
	1000	4.31	1.99	1.77			1
	5000	8.39	2.68	2.51			1
High	200	2.97	1.88	1.66	1.80	3.02	1
	1000	4.23	1.96	1.77			1
	5000	7.99	2.65	2.48			1

	Estimate	Robust standard error
Intercept	-5.159	1.131
Assigned treatment: HAART vs. non-HAART	-0.015	0.549
CD4 count at 1 visit before trial baseline	0.146	0.380
CD4 count at 2 visits before trial baseline	-0.277	0.372
Viral load at 1 visit before trial baseline	0.015	0.354
Viral load at 2 visits before trial baseline	0.615	0.275
Site 2 vs. Site 1	0.503	1.148
Site 3 vs. Site 1	0.071	0.936
Caucasian vs. Black	-0.182	0.757
Other ethnicity vs. Black	0.977	1.078
Interaction between assigned treatment and	-0.004	0.554
CD4 count at 1 visit before trial baseline		

Table 5: Results for the fitted MSM for the sequentially emulated trials using the HERS data. Robust standard error: standard errors based on the sandwich variance estimate.

Supplementary Materials to "Inference procedures in sequential trial emulation with survival outcomes: comparing confidence intervals based on the sandwich variance estimator, bootstrap and jackknife"

> Juliette M. Limozin, Shaun R. Seaman and Li Su MRC Biostatistics Unit University of Cambridge

1 Schematic illustration of sequential trial emulation



Figure 1: A schematic illustration of how patients' data are utilised in sequential trial emulation.

Figure 1 provides a schematic illustration of how patients' data are utilised in sequential trial emulation (STE). Three target trials, starting at visits at time t = 0, 1, 2, were sequentially emulated, which were referred

as 'trial 0', 'trial 1', and 'trial 2'. Patient 1 never initiated treatment for the duration of the study until he/she was lost to follow-up after t = 2, so he/she/they was eligible as a control (marked by the black arrow) in all three trials. Patient 2 initiated treatment (marked by the orange arrow) at t = 0 and kept taking the treatment until the end of follow-up so he/she/they was in the treated group for trial 0 starting at t = 0, but not eligible for trials 1 and 2, starting at t = 1, 2, respectively, under the criterion that patients were only eligible if there was no prior history of treatment. Patient 3 initiated treatment at t = 0 but stopped from t = 1, so his/her/their follow-up was artificially censored from t = 1. Patient 3 was included in the treatment group for trial 0, but his/her data was not included in other trials because he/she/they had a prior history of treatment. Patient 4 was not taking treatment at t = 0 but initiated treatment from t = 1 onwards: hence he/she/they was eligible as a control in trial 0 and artificially censored at the time he/she started treatment, t = 1, and he/she was eligible as a treated patient in trial 1 but not eligible in trial 2.

2 Causal Assumptions

No Interference.

For $i \neq j$, patient *i*'s received treatment has no effect on patient *j*'s potential outcomes [1], i.e., a patient's event time is not affected by other patient's treatments.

Consistency.

 $\forall m, k, \overline{Y}_{m,k} = \overline{Y}_{m,k}^{\overline{A}_{m,k}}$ and $\overline{L}_{m,k} = \overline{L}_{m,k}^{\overline{A}_{m,k}}$, meaning that the observed outcomes $\overline{Y}_{m,k}$ and covariates $\overline{L}_{m,k}$ are equal to their potential outcomes and covariates, under the treatment assignment which they actually received, for every trial visit k in trial m [1, 2].

Positivity.

 $\forall m, k, \Pr\{A_{m,k} = a \mid \overline{A}_{m,k-1} = \overline{a}_{k-1}, V, \overline{L}_{m,k}, Y_{m,k-1} = 0, C_{m,k-1} = 0\} > 0 \text{ and } \Pr\{C_{m,k} = 0 \mid C_{m,k-1} = 0, \overline{A}_{m,k} = \overline{a}_k, V, \overline{L}_{m,k}, Y_{m,k-1} = 0\} > 0, \text{ i.e., a patient has non-zero probability of adhering to the treatment assigned and remaining in the study at all time conditional on the observed histories of treatment and covariates [2].$

Sequentially ignorable treatment assignment.

 $\forall m, k, Y_{m,k}^{\overline{a}_k} \perp A_{m,k} \mid V, \overline{L}_{m,k}, \overline{A}_{m,k-1} = \overline{a}_{k-1}, Y_{m,k-1} = 0, C_{m,k-1} = 0$ for a = 0, 1, i.e., at a given time, conditional on past treatment assignment and covariate history, there is no unmeasured confounding between the potential outcome and the current treatment received [1].

Sequentially ignorable loss to follow up.

 $\forall m, k, \overline{C}_{m,k} \perp Y_{m,k+1}^{\overline{a}_k}, Y_{m,k+2}^{\overline{a}_k}, \dots \mid \overline{C}_{m,k-1} = 0, Y_{m,k} = 0, \overline{A}_{m,k} = \overline{a}_k, V, \overline{L}_{m,k}$, for a = 0, 1 [1]. In other words, at a given time, a patient's probability of being under follow-up does not depend on their future risk of

event, conditional on the treatment and covariate history up to that time.

3 Inverse probability weighting

For addressing artificial censoring due to treatment non-adherence, a patient's stabilised inverse probability of treatment weight [3, 1, 4, 5] at trial visit k (k > 0) in trial m is defined as

$$sw_{m,k}^{A} = \frac{\prod_{j=1}^{k} \Pr(A_{m,j} = a \mid \overline{A}_{m,j-1} = \overline{a}_{j-1}, V, L_{m,0}, E_m = 1, Y_{m,j-1} = 0, C_{m,j-1} = 0)}{\prod_{j=1}^{k} \Pr(A_{m,j} = a \mid \overline{A}_{m,j-1} = \overline{a}_{j-1}, V, \overline{L}_{m,j}, E_m = 1, Y_{m,j-1} = 0, C_{m,j-1} = 0)}, \qquad a \in \{0, 1\}.$$
(1)

Here, $\Pr(A_{m,j} = a \mid \overline{A}_{m,j-1} = \overline{a}_{j-1}, V, \overline{L}_{m,j}, E_m = 1, Y_{m,j-1} = 0, C_{m,j-1} = 0)$ is the conditional probability that the patient's treatment received at trial visit j in trial m remained the same as their treatment received up to trial visit j - 1, conditional on their observed variables up to trial visit j. The baseline covariates V and $L_{m,0}$ in the numerator of (1) are also included as covariates in the MSM of equation (3) of the main text [1].

To address censoring due to loss to follow-up, the stabilised inverse probability of censoring weight [3, 1, 4, 5] for a patient at trial visit k (k > 0) in trial m is

$$sw_{m,k}^{C} = \frac{\prod_{j=0}^{k-1} \Pr(C_{m,j} = 0 \mid C_{m,j-1} = 0, \overline{A}_{m,j} = \overline{a}_j, V, L_{m,0}, E_m = 1, Y_{m,j} = 0)}{\prod_{j=0}^{k-1} \Pr(C_{m,j} = 0 \mid C_{m,j-1} = 0, \overline{A}_{m,j} = \overline{a}_j, V, \overline{L}_{m,j}, E_m = 1, Y_{m,j} = 0)}, \qquad a \in \{0, 1\}.$$
(2)

Here, $\Pr(C_{m,j} = 0 \mid \overline{C}_{m,j-1} = 0, \overline{A}_{m,j} = \overline{a}_j, V, \overline{L}_{m,j}, E_m = 1, Y_{m,j} = 0)$ is the conditional probability that the patient remains in the trial during $[t_{m,j+1}, t_{m,j+2})$ given that they had been in the trial in $[0, t_{m,j+1})$ and their observed covariate history up to time $t_{m,j}$. Again, whenever we condition on certain variables in the numerator of (2), these variables are also be included as covariates in the MSM of equation (3) of the main text.

4 More details for key functions of the TrialEmulation package

- data_preparation: takes longitudinal data and the specifications of the treatment and censoring models as input, and returns an expanded dataset with patients' data spread across their eligible sequentially emulated trials. This dataset includes a column containing the patients' SIPTCWs as calculated from the formulae (4) and (5), according to whether we are conducting an intention-to-treat or per-protocol analysis. The modelling fitting required for calculating SIPTCWs was performed using the original longitudinal data with the variables specified in the function input. For the per-protocol analysis, the expanded data have been artificially censored whenever patients stop adhering to their assigned treatment strategies in each emulated trial. This function implements Steps 1 and 2 of MRD estimation described at the end of Section 3 of the main text.
- trial_msm: takes the expanded data with SIPTCWs such as one returned from data_preparation and the MSM specification such as in equation (3) in the main text as inputs and produces a fit.glm type

output of the MSM with estimated hazard ratios and the sandwich variance matrix estimate. This function implements Step 3 of MRD estimation described at the end of Section 3 of the main text. We can use predict.glm on the output of this function to estimate marginal risks for a target population with given baseline covariate data, which is what we use to carry out Step 5 of the MRD estimation.

• initiators: a wrapper function combining the two functions above.

The data_preparation function in the TrialEmulation package was used to estimate the stabilised IPTWs from the simulated datasets, and this function outputs the expanded and artificially censored data in the sequential trials as described in Section 3 of the main text, with each patient's inverse probability weights at each trial's follow-up visit. The MSM for the discrete-time counterfactual hazard was fitted using the trial_msm function.

The sandwich variance matrix estimate is provided in the output of trial_msm and was used to obtain Sandwich CIs. The code for implementing nonparametric bootstrap CIs, LEF bootstrap CIs and jackknife CIs, were not included in the TrialEmulation package so they were created for the purpose of this article and can be found in the GitHub repository https://github.com/juliettelimozin/Multiple-trial-emulation-IPTW-MSM-CIs. More details on the TrialEmulation package can be found at https://cran.r-project.org/web/packages/ TrialEmulation/TrialEmulation.pdf

5 Pseudo code for the simulation study

Algorithm 1 presents a pseudo-code of the simulation study in Section 5 of the main text. The R code can be

 $found \ at \ \texttt{https://github.com/juliettelimozin/Multiple-trial-emulation-IPTW-MSM-CIs.}$

Algorithm 1 Pseudo-code of Monte Carlo simulation algorithm.
for MC iteration $m = 1, 2,, 1000$ do
for Simulation scenario $l = 1, 2,, 81$ do
Data A \leftarrow Generate data with scenario l
Select eligible patients
Fit models for the denominator and numerator terms of stabilised IPTWs to eligible patients' data up
to the first visit they switched treatment after trial baseline.
Data B \leftarrow the original dataset expanded into data for sequentially emulated trials and assign patients
to eligible trials
for Each trial \mathbf{do}
Artificially censor patients' follow-up when they no longer adhere to the treatment assigned at the
trial baseline
Estimate each patient's stabilised IPTW based on covariate history in this trial. At trial baseline,
the weights are always one.
end for
Fit weighted pooled logistic regression to Data B
$v \leftarrow MRD$ estimate for trial 0 patients
$[B_1, B_2] \leftarrow$ lower- and upper-bound of nonparametric bootstrap pivot CI of MRD
$[LEF_1^{(1)}, LEF_2^{(1)}] \leftarrow$ lower- and upper-bound of LEF bootstrap pivot CI of MRD using approach 1
$[LEF_1^{(2)}, LEF_2^{(2)}] \leftarrow$ lower- and upper-bound of LEF bootstrap pivot CI of MRD using approach 2
$[S_1, S_2] \leftarrow$ lower- and upper-bound of the sandwich-variance-estimator-based CI of MRD
$[J_1^{(1)}, J_2^{(1)}] \leftarrow \text{lower- and upper-bound of jackknife Wald CI of MRD}$
$[J_1^{(2)}, J_2^{(2)}] \leftarrow$ lower- and upper-bound of jackknife MVN CI of MRD
end for
end for
$\mathbf{return} \; v, [B_1, B_2], [LEF_1^{(1)}, LEF_2^{(1)}], [LEF_1^{(2)}, LEF_2^{(2)}], [S_1, S_2], [J_1^{(1)}, J_2^{(1)}], [J_1^{(2)}, J_2^{(2)}]$

6 Additional simulation results

6.1 Data tabulation of sequentially emulated trials in simulations

Tables 1–9 provide examples of data prepared for sequentially emulated trials using simulated data in Section 3 of the main text. Data are aggregated across trials and tabulated by treatment arm, trial visit and outcome status in various simulation scenarios.

Table 1: Data tabulation by treatment arm and outcome status when generating one dataset using the data generating algorithm in Table 2 of the Main Text for small sample sizes (n = 200) under low event rate.

					Trial visit					
Sample size	Confounding strength	Treatment prevalence	Assigned treatment	Outcome		0	1	2	3	4
200	0.1	-1	0	0		409	269	172	98	43
				1		5	4	1	0	0
			1	0		148	34	11	2	1
				1		4	2	0	0	0
		0	0	0		162	77	37	16	5
				1		5	2	1	0	0
			1	0		190	89	45	25	7
				1		0	0	0	1	0
		1	0	0		85	29	8	3	1
				1		0	0	0	0	0
			1	0		198	149	108	74	42
				1		1	2	0	0	0
	0.5	-1	0	0		400	254	156	84	34
				1		3	2	0	0	0
			1	0		162	40	11	2	0
				1		1	2	1	0	0
		0	0	0		200	98	47	21	8
				1		2	1	0	0	0
			1	0		187	101	47	24	12
				1		3	0	1	0	0
		1	0	0		81	29	11	5	2
				1		0	0	0	0	0
			1	0		196	130	95	64	36
			0	1		2	1	0	2	0
	0.9	-1	0	0		397	257	156	86	37
				1		1	1	0	0	0
			1	0		160	34	11	2	0
		0	0	1		2	1	10	0	10
		0	0	0		194	99	49	25	10
			1	1		105	2	1 26	16	0
			1	0		180	80	30	10	5
		1	0	1		07	2	1	0	0
		1	U	1		97	3U 0	9	4	2
			1	1		107	150	07	U E 0	0 90
			1	1		197	190	97	86 0	28
				1		1	2	1	0	U

					Trial visit					
Sample size	Confounding strength	Treatment prevalence	Assigned treatment	Outcome		0	1	2	3	4
1000	0.1	-1	0	0		2058	1357	839	462	193
				1		35	24	16	9	5
			1	0		765	188	41	7	2
				1		7	2	2	0	0
		0	0	0		952	480	239	111	42
				1		13	6	3	0	0
			1	0		937	473	231	91	42
				1		8	5	3	2	0
		1	0	0		357	81	13	2	0
			_	1		6	0	0	0	0
			1	0		991	727	536	358	222
	0 F		0	1		3	7	5	5	0
	0.5	-1	0	0		1960	1265	758	412	173
			1	1		27	20	10	6 10	1
			1	0		10	190	45	10	2
		0	0	1		10		911	0	20
		0	0	0		977	404	211	00	29
			1	1		051	450	183	2 82	26
			1	1		301 8	400	100	02	20
		1	0	0		398	114	31	10	2
		1	0	1		6	2	1	10	õ
			1	0		978	687	462	304	168
			-	ĩ		14	3	6	2	2
	0.9	-1	0	0		1897	1215	730	394	161
				1		24	9	8	4	0
			1	0		799	189	49	8	1
				1		16	2	0	0	0
		0	0	0		968	475	219	83	26
				1		17	6	2	0	0
			1	0		939	414	170	68	19
				1		18	7	1	1	0
		1	0	0		436	134	43	13	2
				1		0	0	0	0	0
			1	0		987	633	406	250	131
				1		11	5	3	8	2

Table 2: Data tabulation by treatment arm and outcome status when generating one dataset using the data generating algorithm in Table 2 of the Main Text for medium sample sizes (n = 1000) under low event rate.

					I riai visit					
Sample size	Confounding strength	Treatment prevalence	Assigned treatment	Outcome		0	1	2	3	4
5000	0.1	-1	0	0		10181	6601	4075	2273	961
				1		119	70	43	23	13
			1	0		3891	976	250	49	12
				1		29	6	2	2	1
		0	0	0		4949	2446	1171	522	177
				1		52	22	12	8	3
			1	0		4732	2251	1052	477	145
				1		39	18	13	2	2
		1	0	0		1932	557	168	47	11
				1		27	6	1	0	0
			1	0		4912	3531	2545	1797	1028
				1		50	20	31	11	14
	0.5	-1	0	0		10134	6539	3992	2193	916
				1		135	85	50	24	11
			1	0		3902	934	201	36	3
				1		47	5	4	0	0
		0	0	0		4858	2388	1144	517	185
				1		65	32	16	6	2
			1	0		4698	2151	973	406	127
				1		52	16	17	7	5
		1	0	0		1931	545	153	42	10
				1		30	6	2	0	0
			1	0		4911	3426	2365	1568	865
				1		49	30	20	17	14
	0.9	-1	0	0		9673	6170	3729	2051	842
				1		151	100	60	37	17
			1	0		3922	925	205	50	10
				1		85	10	2	0	0
		0	0	0		4695	2267	1050	462	151
			_	1		55	27	9	4	1
			1	0		4727	1986	846	336	104
				1		67	29	9	7	0
		1	0	0		2183	644	196	53	15
				1		20	7	0	0	0
			1	0		4894	3147	1985	1231	603
				1		71	42	34	18	15

Table 3: Data tabulation by treatment arms and outcome status when generating one dataset using the data generating algorithm in Table 2 of the Main Text for large sample sizes (n = 5000) under low event rate.

				Trial visit					
Sample size	Confounding strength	Treatment prevalence	Assigned treatment	Outcome	0	1	2	3	4
200	0.1	-1	0	0	391	253	157	87	36
				1	12	8	4	3	1
			1	0	150	32	7	1	0
				1	2	1	0	0	0
		0	0	0	183	89	47	22	8
				1	8	6	2	2	0
			1	0	179	87	40	14	6
				1	5	4	1	0	0
		1	0	0	87	32	13	4	1
				1	2	0	0	0	0
			1	0	191	138	102	71	46
				1	6	3	1	1	1
	0.5	1	0	0	417	976	177	100	44
	0.5	-1	0	1	14	210	4	3	44
			1	0	130	20	7	2	Õ
			1	1	3	0	0	1	0
		0	0	0	106	102	53	20	11
		0	0	1	4	3	2	0	0
			1	0	179	82	25	8	0
				1	6	0	2	0	0
		1	0	0	70	18	5	1	0
		-	Ŷ	1	2	0	Ő	0	Ő
			1	0	195	134	104	71	37
				1	3	4	0	1	0
	0.0	1	0	0	357	226	136	79	30
	0.5	-1	0	1	6	3	3	2	0
			1	0	156	46	8	2	1
			-	1	6	4	1	0	0
		0	0	0	178	70	36	13	3
		0	0	1	5	4	0	10	0
			1	0	181	80	34	14	2
			-	1	11	3	4	0	0
		1	0	0	81	27	Q	Δ	0
		1	v	1	1	0	0	0	0
			1	0	190	122	80	41	21
			-	1	9	5	3	1	1

Table 4: Data tabulation by treatment arms and outcome status when generating one dataset using the data generating algorithm in Table 2 of the Main Text for small sample sizes (n = 200) under medium event rate.

					Trial visit					
Sample size	Confounding strength	Treatment prevalence	Assigned treatment	Outcome		0	1	2	3	4
1000	0.1	-1	0	0		2012	1321	825	460	194
				1		66	40	20	11	3
			1	0		722	176	37	6	1
				1		18	8	1	0	0
		0	0	0		1002	505	257	127	44
				1		32	17	5	1	0
			1	0		902	412	179	73	25
				1		22	8	4	0	0
		1	0	0		360	86	20	4	1
			1	1		9	3 CC0	459	910	100
			1	0		972	10	453	312	182
	05	1	0	1		18	19	10 779	417	0 170
	0.5	-1	0	0		1997	1270	112	417	1/0
			1	0		752	172	37	10	2
			1	1		26	5	3	10	0
		0	0	0		997	506	249	113	37
		0	0	1		22	9	3	2	2
			1	0		913	397	173	76	31
				1		28	11	0	3	2
		1	0	0		402	117	31	6	1
				1		16	2	1	0	0
			1	0		951	642	423	272	144
				1		32	16	11	5	5
	0.9	-1	0	0		1742	1093	662	363	151
				1		65	41	21	13	5
			1	0		755	179	48	11	3
				1		29	11	1	1	0
		0	0	0		937	453	223	108	41
			_	1		16	7	3	1	1
			1	0		905	409	177	56	13
		1	0	1		38	112	5	2	0
		1	U	0		409	113	33	6	1
			1	1		9	609	20E	0 926	191
			1	1		952 38	16	090 15	∠30 0	121
				T		38	10	19	9	0

Table 5: Data tabulation by treatment arms and outcome status when generating one dataset using the data generating algorithm in Table 2 of the Main Text for medium sample sizes (n = 1000) under medium event rate.

					Trial visit					
Sample size	Confounding strength	Treatment prevalence	Assigned treatment	Outcome		0	1	2	3	4
5000	0.1	-1	0	0		9935	6440	3976	2209	934
				1		298	178	98	49	16
			1	0		3679	911	215	42	7
				1		89	24	7	1	0
		0	0	0		4736	2298	1076	472	161
				1		127	48	22	13	3
			1	0		4624	2257	1037	445	132
				1		88	55	18	15	1
		1	0	0		1741	454	125	35	7
				1		59	10	2	0	0
			1	0		4826	3458	2427	1645	913
	05	1	0	1		108	58	61	40	29
	0.5	-1	0	0		9471	10047	3055	1988	809
			1	1		299 2705	180	117	07 49	20
			1	0		3783	904	224	40	1
		0	0	1		4797	21	1077	477	164
		0	0	1		120	2250 50	30	11	3
			1	0		4570	2069	906	359	125
			1	1		137	47	25	12	3
		1	0	0		1846	497	124	32	9
				1		47	8	2	0	Õ
			1	0		4820	3247	2179	1380	748
				1		124	64	45	32	20
	0.9	-1	0	0		8950	5602	3328	1769	710
				1		297	165	93	55	24
			1	0		3813	907	201	38	7
				1		180	30	6	3	3
		0	0	0		4795	2318	1124	485	166
				1		124	47	19	7	1
			1	0		4547	1917	805	304	84
				1		163	80	14	13	8
		1	0	0		2041	615	192	58	16
			_	1		47	10	6	3	1
			1	0		4775	3030	1941	1185	592
				1		162	81	50	41	20

Table 6: Data tabulation by treatment arms and outcome status when generating one dataset using the data generating algorithm in Table 2 of the Main Text for large sample sizes (n = 5000) under medium event rate.

					Trial visit					
Sample size	Confounding strength	Treatment prevalence	Assigned treatment	Outcome		0	1	2	3	4
200	0.1	-1	0	0		345	213	126	67	28
				1		17	13	7	4	1
			1	0		148	32	14	3	1
				1		7	2	1	1	0
		0	0	0		187	95	46	20	5
				1		12	2	2	0	0
			1	0		180	83	33	14	5
				1		3	5	2	2	1
		1	0	0		71	20	6	1	0
				1		3	0	0	0	0
			1	0		188	121	83	49	29
				1		9	8	4	3	1
	0.5	-1	0	0		354	226	140	80	34
				1		23	14	9	5	2
			1	0		135	31	5	2	0
				1		8	1	1	0	0
		0	0	0		192	96	45	19	7
				1		13	4	1	1	0
			1	0		173	81	36	7	2
				1		7	4	1	1	0
		1	0	0		55	12	5	1	0
				1		1	0	0	0	0
			1	0		188	127	82	55	36
				1		11	9	4	3	0
	0.9	-1	0	0		377	238	145	75	31
				1		24	14	8	6	4
			1	0		136	24	6	1	0
				1		9	1	0	0	0
		0	0	0		187	91	46	20	6
				1		10	4	3	2	0
			1	0		172	72	30	6	2
				1		12	2	2	3	0
		1	0	0		74	18	0	0	0
				1		4	2	1	0	0
			1	0		188	125	74	49	24
				1		8	10	6	1	0

Table 7: Data tabulation by treatment arms and outcome status when generating one dataset using the data generating algorithm in Table 2 of the Main Text for small sample sizes (n = 200) under high event rate. Trial visit

Sample size C					11101 11510					
Sample Size C	Confounding strength	Treatment prevalence	Assigned treatment	Outcome		0	1	2	3	4
1000 0.	.1	-1	0	0		1865	1198	722	393	165
				1		105	55	33	18	7
			1	0		695	154	27	6	0
				1		35	6	1	0	0
		0	0	0		802	373	167	69	23
				1		42	11	7	2	1
			1	0		894	421	199	95	41
				1		41	10	9	5	1
		1	0	0		365	109	33	10	3
				1		22	3	1	0	0
			1	0		925	627	431	277	156
				1		50	29	19	14	10
0.	.5	-1	0	0		1871	1178	709	382	158
				1		99	57	30	13	5
			1	0		695	159	34	3	1
		0	0	1		48	6	4	0	0
		0	0	0		828	381	169	74	26
			1	1		43	20	171	4	14
			1	0		880 46	390	1/1	02	14
		1	0	1		40 246	10	4 92	4 E	1
		1	0	0		540 24	95	20	0	0
			1	1		019	599	2027	256	126
			1	1		912 54	31	307	230	120
0	0	-1	0	0		1608	1034	612	330	132
0.	.0	1	0	1		105	62	27	14	7
			1	0		712	144	33	11	3
			-	1		51	18	4	0	0
		0	0	0		899	417	184	79	28
				1		59	27	12	4	0
			1	0		850	357	151	45	15
				1		63	34	3	7	1
		1	0	0		457	155	48	18	7
				1		20	5	2	1	0
			1	0		919	565	355	217	118
				1		54	41	20	11	8

Table 8: Data tabulation by treatment arms and outcome status when generating one dataset using the data generating algorithm in Table 2 of the Main Text for medium sample sizes (n = 1000) under high event rate.

					Trial visit					
Sample size	Confounding strength	Treatment prevalence	Assigned treatment	Outcome		0	1	2	3	4
5000	0.1	-1	0	0		9584	6122	3754	2069	851
				1		593	356	188	85	40
			1	0		3378	763	171	28	5
				1		178	43	4	3	0
		0	0	0		4440	2076	951	395	129
				1		249	111	42	21	1
			1	0		4426	2069	949	395	143
				1		196	80	48	33	7
		1	0	0		1739	471	125	34	9
				1		89	25	10	1	0
			1	0		4687	3258	2277	1508	845
				1		215	146	110	78	35
	0.5	-1	0	0		9292	5884	3571	1958	808
				1		574	341	193	93	39
			1	0		3428	786	170	35	5
				1		190	48	11	2	1
		0	0	0		4482	2112	997	452	157
				1		261	97	45	23	6
			1	0		4382	1972	859	321	105
				1		200	90	35	13	2
		1	0	0		1772	484	131	29	6
				1		106	20	5	1	0
			1	0		4644	3119	2033	1328	746
				1		244	134	122	51	34
	0.9	-1	0	0		8655	5343	3152	1676	672
				1		545	317	172	94	45
			1	0		3451	769	192	42	7
				1		332	56	13	5	2
		0	0	0		4517	2133	971	405	129
				1		256	114	46	17	7
			1	0		4295	1776	704	253	78
				1		320	94	43	20	4
		1	0	0		1920	528	161	44	10
				1		107	19	9	2	0
			1	0		4558	2802	1696	1013	475
				1		325	167	90	54	27

Table 9: Data tabulation by treatment arms and outcome status when generating one dataset using the data generating algorithm in Table 2 of the Main Text for large sample sizes (n = 5000) under high event rate. Trial visit

6.2 CI coverage in medium and high event rate scenarios

Figures 2 and 3 present the empirical coverage rates of the CIs when the event rates were medium and high, respectively.









6.3 Bias-eliminated CI coverage

Figures 4–6 present bias-eliminated coverage rates under different outcome rate scenarios.







applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of Jackknife resampling; Jackknife MVN: CIs constructed by applying Approach 2 of Jackknife resampling; Sandwich: CIs based on the sandwich Figure 5: Bias-eliminated coverage of the CIs under medium event rates. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by variance estimator





6.4 Empirical standard deviation and MSE of the MRD estimates

For all scenarios examined, the empirical standard deviations (Figure 7) were always higher at later visits than at earlier visits. There are a few possible reasons for this: 1) due to the non-collapsibility of logistic models, we were not able to specify an exactly correct MSM of the potential outcomes parameterised by the discrete-time hazard. Instead, we used a rich model stratified by trial visits, which led to data sparsity and larger variability in MRD estimates at later visits. 2) Only earlier trials had data at longer follow-up trial visits, so the information was scarce by design. 3) As mentioned previously, we rely on IPW to estimate the MRD. The limited amount of observations at later visits paired with the increased imbalance between the treatment groups likely resulted in the estimated weights for later trials visits being larger and more variable. Consequently, the larger magnitude and variability of the weights at later visits could contribute to the unstable estimation of the MRD.

The patterns of empirical standard deviations largely followed those of empirical biases across treatment prevalence and confounding strength scenarios. That is, the scenarios with larger biases also exhibited larger standard deviations. Overall, the impact of treatment prevalence on empirical standard deviations was more prominent than that of confounding strength, possibly due to the small range we specified for the coefficients of the time-varying confounder in the treatment and outcome processes. Interestingly, the empirical standard deviations increased when event rates were higher, when fixing the sample size, treatment prevalence and confounding strength. This phenomenon might be explained by that more patients from the untreated group were depleted from the at-risk sets due to more event occurrences, which resulted in larger treatment group imbalances at later visits. As expected, larger sample sizes mitigated this variability by providing more information. Results for the root-MSE were consistent with the results for bias and empirical standard deviations and can be found in Figure 8.









6.5 Ratio of estimated standard errors to the empirical standard deviation of the MRD estimator

Figure 9 presents the SE ratio results in the scenarios with low event rate and moderate/large sample sizes. Figure 10–15 present the SE ratio results in the medium and high event rate scenarios.



respectively. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of jackknife resampling; Sandwich: CIs based on Figure 9: Ratio of the estimated standard error to empirical standard deviation of the MRD estimator (SE ratio) in low event rate and medium/large sample size scenarios (n = 1000, 5000). The dots represent the averages of the ratio, with the bottom and top of the bar being the 1st and 3rd quartile of this ratio the sandwich variance estimator.



Figure 10: Ratio of the estimated standard error to empirical standard deviation of the MRD estimator (SE ratio) in **medium event rate and small sample size scenarios**. The dots represent the averages of the ratio, with the bottom and top of the bar being the 1st and 3rd quartile of this ratio respectively. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of jackknife resampling; Sandwich: CIs based on the sandwich variance estimator.



Figure 11: Ratio of the estimated standard error to empirical standard deviation of the MRD estimator (SE ratio) in **medium event rate and small sample size scenarios**. The dots represent the averages of the ratio, with the bottom and top of the bar being the 1st and 3rd quartile of this ratio respectively. Jackknife MVN: CIs constructed by applying Approach 2 of jackknife resampling.



sample size scenarios (n = 1000, 5000). The dots represent the averages of the ratio, with the bottom and top of the bar being the 1st and 3rd quartile of this Figure 12: Ratio of the estimated standard error to empirical standard deviation of the MRD estimator (SE ratio) in medium event rate and medium/large ratio respectively. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of jackknife resampling; Sandwich: CIs based on the sandwich variance estimator.



Figure 13: Ratio of the estimated standard error to empirical standard deviation of the MRD estimator (SE ratio) in **high event rate and small sample size scenarios**. The dots represent the averages of the ratio, with the bottom and top of the bar being the 1st and 3rd quartile of this ratio respectively. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of jackknife resampling; Sandwich: CIs based on the sandwich variance estimator.



Figure 14: Ratio of the estimated standard error to empirical standard deviation of the MRD estimator (SE ratio) in **high event rate and small sample size scenarios**. The dots represent the averages of the ratio, with the bottom and top of the bar being the 1st and 3rd quartile of this ratio respectively. Jackknife MVN: CIs constructed by applying Approach 2 of jackknife resampling.



Figure 15: Ratio of the estimated standard error to empirical standard deviation of the MRD estimator (SE ratio) in high event rate and medium/large sample size scenarios (n = 1000, 5000). The dots represent the averages of the ratio, with the bottom and top of the bar being the 1st and 3rd quartile of this ratio respectively. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of jackknife resampling; Sandwich: CIs based on the sandwich variance estimator.

6.6 Monte Carlo standard error of the CI coverage

Finally, to assess whether lower-than-nominal coverage in some simulation scenarios may be due to uncertainty induced by Monte Carlo simulation error, we calculated and illustrated the standard errors of empirical coverage rates in Figures 16–18. We observe minimal Monte Carlo standard errors across all simulation scenarios, with the error mostly remaining at 1.5%, especially for small sample sizes where we did not observe much difference in Monte Carlo errors between the CI methods. According to the Monte Carlo standard error of 1.5% or less across the simulations, then $n_{sim} = \frac{95(100-95)}{1.5^2} = 211$ simulations are required [6]. As a result, 1000 simulations were sufficient to theoretically achieve nominal coverage with a Monte Carlo error of at most 1.5% across the simulations. We also observed lower Monte Carlo errors at earlier visits in large sample size (n = 5000) scenarios. As the outcome event rate increased, the Monte Carlo errors converged to similar values for all CI methods as well.










by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Figure 18: Monte Carlo standard error the CI coverage under high event rates. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed Approach 1 of Jackknife resampling; Jackknife MVN: CIs constructed by applying Approach 2 of Jackknife resampling; Sandwich: CIs based on the sandwich variance estimator

6.7 Convergence issues

During the simulations, we encountered estimation errors when the glm function in R was used by the trial_msm function of the TrialEmulation package to estimate the MSM parameters in small sample size scenarios (n = 200). The MSM parameters $\beta_{1,3}$ and $\beta_{1,4}$ in equation (11) of the main text were often inestimable in such scenarios due to data sparsity issues. When such errors occurred, the default in the predict.glm function used for estimating the MRD was to treat the inestimable parameters as equal to 0. Therefore, we are still able to estimate the MRD and construct nonparametric bootstrap CIs, LEF bootstrap CIs and Jackknife Wald CIs. However, the data sparsity issues also led to difficulty to construct Sandwich CIs because of non-positive definiteness and non-symmetry of the variance matrices.

From Tables 10, 11 and 12, we see that, whilst we encountered little to no convergence issues when constructing nonparametric bootstrap CIs, LEF bootstrap CIs and Jackknife Wald CIs for all data scenarios, there were substantially more problems of non-positive definiteness and non-symmetry when computing the sandwich variance matrices. This led to a high rate of failures, ranging from 3 to 81%, in constructing the Sandwich CIs as the multivariate normal distribution for sampling requires a symmetric, positive definite variance matrix. There were problems with these matrix properties for more than half of the simulations when the sample size was n = 200, whilst the failure rate for sample size n = 1000 was between 3% and 37%. Although we have not included the failure rates by confounding strength, we note that the failure rate for the Sandwich CIs was further exacerbated in scenarios with n = 200 and high treatment prevalence, averaging at around 81%. On occasion, we observed that this was due to **R** being too restrictive with the matrix properties. In some cases, the sandwich variance matrix was almost symmetric with differences between symmetric values at a negligible magnitude of 10^{-4} , so discarding the results based on such a difference and forcing a symmetric matrix for Sandwich CIs may have been judicious, and may have modified the coverage rate results for these CIs slightly. For very large sample sizes n = 5000, the failure rate was negligible across all CI methods.

Jackknife MVN CIs also encountered many construction issues, where for low and high treatment prevalence scenarios, this method failed for roughly half of the simulations, making it unreliable for such simulation scenarios. These construction issues were often due to the treatment coefficients at the later visits (k = 3, 4) in the MSM being inestimable in some jackknife samples. Therefore the jackknife variance estimate in equation (11) of the main text could not be calculated.

Table 10: Proportions of simulations with CI construction failures in **low event rate scenarios, aggregated by sample size and treatment prevalence**. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of Jackknife resampling; Jackknife MVN: CIs constructed by applying Approach 2 of Jackknife resampling; Sandwich: CIs based on the sandwich variance estimator

Outcome event	Sample size	Treatment	Bootstrap	LEF outcome	LEF both	Sandwich	Jackknife MVN	Jackknife Wald
rate		prevalence						
Low	200	-1	0.00	0.00	0.00	0.07	0.46	0.00
			0.00	0.00	0.00	0.07	0.46	0.00
			0.00	0.00	0.00	0.07	0.46	0.00
		0	0.00	0.00	0.00	0.27	0.03	0.00
			0.00	0.00	0.00	0.27	0.03	0.00
			0.00	0.00	0.00	0.27	0.03	0.00
		1	0.00	0.00	0.00	0.81	0.51	0.00
			0.00	0.00	0.00	0.81	0.51	0.00
			0.00	0.00	0.00	0.81	0.51	0.00
	1000	-1	0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
		0	0.00	0.00	0.00	0.03		
			0.00	0.00	0.00	0.03		
			0.00	0.00	0.00	0.03		
		1	0.00	0.00	0.00	0.37		
			0.00	0.00	0.00	0.37		
			0.00	0.00	0.00	0.37		
	5000	-1	0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
		0	0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
		1	0.00	0.00	0.00	0.01		
			0.00	0.00	0.00	0.01		
			0.00	0.00	0.00	0.01		

Table 11: Proportions of simulations with CI construction failures in **medium event rate scenarios**, aggregated by sample size and treatment prevalence. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of Jackknife resampling; Jackknife MVN: CIs constructed by applying Approach 2 of Jackknife resampling; Sandwich: CIs based on the sandwich variance estimator

Outcome event	Sample size	Treatment	Bootstrap	LEF outcome	LEF both	Sandwich	Jackknife MVN	Jackknife Wald
rate		prevalence						
Medium	200	-1	0.00	0.00	0.00	0.04	0.47	0.00
			0.00	0.00	0.00	0.04	0.47	0.00
			0.00	0.00	0.00	0.04	0.47	0.00
		0	0.00	0.00	0.00	0.12	0.06	0.00
			0.00	0.00	0.00	0.12	0.06	0.00
			0.00	0.00	0.00	0.12	0.06	0.00
		1	0.00	0.00	0.00	0.63	0.51	0.00
			0.00	0.00	0.00	0.63	0.51	0.00
			0.00	0.00	0.00	0.63	0.51	0.00
	1000	-1	0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
		0	0.00	0.00	0.00	0.01		
			0.00	0.00	0.00	0.01		
			0.00	0.00	0.00	0.01		
		1	0.00	0.00	0.00	0.10		
			0.00	0.00	0.00	0.10		
			0.00	0.00	0.00	0.10		
	5000	-1	0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
		0	0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
		1	0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		

Table 12: Proportions of simulations with CI construction failures in **high event rate scenarios, aggregated by sample size and treatment prevalence**. Bootstrap: CIs constructed by nonparametric bootstrap; LEF both: CIs constructed by applying Approach 2 of LEF bootstrap; LEF outcome: CIs constructed by applying Approach 1 of LEF bootstrap; Jackknife Wald: CIs constructed by applying Approach 1 of Jackknife resampling; Jackknife MVN: CIs constructed by applying Approach 2 of Jackknife resampling; Sandwich: CIs based on the sandwich variance estimator

Outcome event	Sample size	Treatment	Bootstrap	LEF outcome	LEF both	Sandwich	Jackknife MVN	Jackknife Wald
rate		prevalence						
High	200	-1	0.00	0.00	0.00	0.04	0.46	0.00
			0.00	0.00	0.00	0.04	0.46	0.00
			0.00	0.00	0.00	0.04	0.46	0.00
		0	0.00	0.00	0.00	0.07	0.08	0.00
			0.00	0.00	0.00	0.07	0.08	0.00
			0.00	0.00	0.00	0.07	0.08	0.00
		1	0.00	0.00	0.00	0.41	0.50	0.00
			0.00	0.00	0.00	0.41	0.50	0.00
			0.00	0.00	0.00	0.41	0.50	0.00
	1000	-1	0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
		0	0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
		1	0.00	0.00	0.00	0.03		
			0.00	0.00	0.00	0.03		
			0.00	0.00	0.00	0.03		
	5000	-1	0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
		0	0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
		1	0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		
			0.00	0.00	0.00	0.00		

Target trial protocol to estimate the per-protocol effect of HAART 7 on all-cause mortality using the HERS data

Table 13: Protocol of a target trial to estimate the per-protocol effect of HAART on all-cause mortality				
Eligibility criteria	HIV-infected women with no prior history of HAART.			
Treatment strategies	Patients in the treatment arm will receive HAART throughout the trial. Patients in the control arm will not receive HAART during the trial (but may take other antiviral treatments).			
$Assignment\ procedures$	Patients will be randomly assigned to either treatment strategy at baseline and will be aware of the strategy to which they have been assigned.			
Follow-up period	Patients are followed from treatment randomisation at baseline visit, for a course of 5 visits spaced 6 months apart, or until event or loss to follow-up, whichever occurs first.			
Outcome	Death from any cause			
Causal contrast of interest	Per-protocol effect of sustained HAART treatment on all-cause mortality			
Statistical Methods	Patients' follow-up will be artificially censored at the time they deviate from their assigned treatment strategy at baseline. IPW using time- varying covariates will be used to address the selection bias caused by this artificial censoring and dependent censoring due to patient's loss to follow-up.			

-- . . -- ---

References

- [1] Daniel R, Cousens S, De Stavola B et al. Methods for dealing with time-dependent confounding. Statistics in Medicine 2013; 32(9): 1584-1618. doi:10.1002/sim.5686.
- [2] Young JG and Tchetgen Tchetgen EJ. Simulation from a known Cox MSM using standard parametric models for the g-formula. Statistics in Medicine 2014; 33(6): 1001–1014. doi:10.1002/sim.5994.
- [3] Danaei G, Rodríguez LAG, Cantero OF et al. Observational data for comparative effectiveness research: An emulation of randomised trials of statins and primary prevention of coronary heart disease. Statistical Methods in Medical Research 2013; 22(1): 70–96. doi:10.1177/0962280211403603.
- [4] Murray EJ, Caniglia EC and Petito LC. Causal survival analysis: A guide to estimating intention-to-treat and per-protocol effects from randomized clinical trials with non-adherence. Research Methods in Medicine & Health Sciences 2021; 2(1): 39-49. doi:10.1177/2632084320961043.
- [5] Robins JM, Hernán MA and Brumback B. Marginal Structural Models and Causal Inference in Epidemiology. Epidemiology 2000; 11(5): 550-560. doi:10.1097/00001648-200009000-00011.
- [6] Morris TP, White IR and Crowther MJ. Using simulation studies to evaluate statistical methods. *Statistics* in Medicine 2019; 38(11): 2074-2102. doi:10.1002/sim.8086.